var title_f40_3_41008="Prenatal ultrasound normal kidneys longitudinal";
var content_f40_3_41008=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F64756&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F64756&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Prenatal ultrasound longitudinal view, bilateral normal kidneys second trimester",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 342px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bilateral normal kidneys (arrows) in the second trimester on longitudinal view. The sonolucent center represents urine in the renal pelvis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Tulin Ozcan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_3_41008=[""].join("\n");
var outline_f40_3_41008=null;
var title_f40_3_41009="Blood supply to the urethra";
var content_f40_3_41009=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F53027&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F53027&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Blood supply to the urethra",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 459px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The uretha is supplied proximally by the bulbar arteries which are branches of the penile artery. The distal urethra is perfused by retrograde flow from the dorsal penile artery.",
"    <br>",
"     By convention, the surfaces of the penis are defined with the penis extended cranially; the urethra is ventrally located.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_3_41009=[""].join("\n");
var outline_f40_3_41009=null;
var title_f40_3_41010="Emollients: Drug information";
var content_f40_3_41010=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Emollients: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F10925285\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Atopiclair&reg;;",
"     </li>",
"     <li>",
"      Atrapro&trade; Antipruritic;",
"     </li>",
"     <li>",
"      Aurstat&reg;;",
"     </li>",
"     <li>",
"      Biafine&reg;;",
"     </li>",
"     <li>",
"      Eletone&reg;;",
"     </li>",
"     <li>",
"      EpiCeram&reg; Skin Barrier;",
"     </li>",
"     <li>",
"      HylatopicPlus&trade;;",
"     </li>",
"     <li>",
"      HylatopicPlus&trade; -Aurstat [DSC];",
"     </li>",
"     <li>",
"      Hylatopic&trade;;",
"     </li>",
"     <li>",
"      Mimyx&reg; [DSC];",
"     </li>",
"     <li>",
"      Neosalus&reg;;",
"     </li>",
"     <li>",
"      Normlshield&reg;;",
"     </li>",
"     <li>",
"      Promiseb&trade;;",
"     </li>",
"     <li>",
"      PruClair&trade;;",
"     </li>",
"     <li>",
"      PruMyx&trade;;",
"     </li>",
"     <li>",
"      PruTect&trade;;",
"     </li>",
"     <li>",
"      PR&trade; Cream;",
"     </li>",
"     <li>",
"      Tropazone&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F10913090\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Skin and Mucous Membrane Agent, Miscellaneous;",
"     </li>",
"     <li>",
"      Topical Skin Product",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F10913112\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topical: Apply to affected area(s) liberally 2-3 times daily, or as needed.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F10925286\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Aerosol, foam, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     HylatopicPlus&trade;:  (100 g, 150 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hylatopic&trade;:  (100 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neosalus&reg;:  (70 g, 200 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Aerosol, foam, topical [kit]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     HylatopicPlus&trade; -Aurstat:  (100 g [DSC]) [packaged with Aurstat gel]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Atopiclair&reg;:  (100 g) [dye free; contains shea nut derivatives]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Eletone&reg;:  (100 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     HylatopicPlus&trade;:  (100 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neosalus&reg;:  (100 g, 180 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Normlshield&reg;:  (120 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Promiseb&trade;:  (30 g) [contains shea nut derivatives]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     PruClair&trade;:  (100 g) [contains shea nut derivatives]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     PR&trade; Cream:  (56.7 g) [packaged with moisturizing cream]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tropazone&trade;:  (120 g) [contains ethanol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mimyx&reg;:  (140 g [DSC])",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     PruMyx&trade;:  (140 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Emulsion, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Biafine&reg;:  (45 g, 90 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     EpiCeram&reg; Skin Barrier:  (50 g, 90 g, 100 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     PruTect&trade;:  (45 g, 90 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Atrapro&trade; Antipruritic:  (113 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aurstat&reg;:  (225 mL) [packaged with HylatopicPlus&trade; cream]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lotion, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neosalus&reg;:  (236 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tropazone&trade;:  (140 g)",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10913113\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not apply within 4 hours of a radiation treatment. Some agents may dissolve fuchsin dye, which is used to define the margins of the radiation fields. Consult physician prior to use if patient undergoing radiation therapy involving use of fuchsin dye.  If skin is broken, cover with a dressing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Foam: Read instructions carefully as certain products require priming of the device before use.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10913091\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Counteract dryness and itchy skin; lubricate and moisturize skin; aid in protection and healing of superficial wounds, burns, and minor abrasions; relief of itching, burning, and pain experienced with various types of dermatoses (including atopic dermatitis, allergic contact dermatitis, and radiation dermatitis); dermal donor and graft site management",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F10913085\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Biafine: Topical emulsion [U.S.], but also a brand name for trolamine [multiple international markets]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F10913105\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined: Dermatologic: Burning, erythema, pruritus, rash, tingling, swelling, urticaria",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10913092\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10913093\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Cancer:  Radiation therapy: Do not apply within 4 hours of radiation treatment. These agents dissolve fuchsin, a dye used to define the margins of the radiation fields.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Skin grafts: Do not apply to dermal grafts until graft has successfully taken.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Infection: If clinical signs of infection are present, appropriate anti-infective should be initiated. Use of these agents may continue during anti-infective therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Shea nut oil: Atopiclair&reg;, Promiseb&trade;, and PruClair&trade; contain shea butter, a product of shea nut oil. If patient has a known allergy to tree nuts or nut oils, consult physician prior to administration.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299257\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F11304574\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322869\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Normlshield External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4.5% (113 g): $5.61",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16082 Version 24.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-17F8E0A872-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_3_41010=[""].join("\n");
var outline_f40_3_41010=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10925285\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10913090\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10913112\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10925286\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10913113\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10913091\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10913085\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10913105\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10913092\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10913093\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299257\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11304574\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322869\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16082\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16082|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_3_41011="Desoximetasone: Patient drug information";
var content_f40_3_41011=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"15\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Desoximetasone: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24740?source=see_link\">",
"     see \"Desoximetasone: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F157972\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Topicort&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F157973\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Desoxicream;",
"     </li>",
"     <li>",
"      Topicort&reg;;",
"     </li>",
"     <li>",
"      Topicort&reg; Gel;",
"     </li>",
"     <li>",
"      Topicort&reg; Mild;",
"     </li>",
"     <li>",
"      Topicort&reg; Ointment",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10012056\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat skin rashes.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10012055\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701912",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to desoximetasone or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10012060\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696817",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use coverings (bandages, dressings, make-up) unless told to do so by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10012061\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10012063\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698659",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired, weak, or touchy; trembling; having a fast heartbeat, confusion, sweating, or dizziness if you missed a dose or recently stopped this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10012058\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694772",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. Use on your skin only. Keep out of your mouth, nose, and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696250",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use. Do not wash your hands after use if putting this on your hand.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Clean affected part before use. Make sure to dry well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694440",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put a thin layer on the affected skin and rub in gently.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10012059\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696441",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put on a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696452",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not put on 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10012064\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10012065\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12363 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-217.16.9.173-D52E307D49-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_3_41011=[""].join("\n");
var outline_f40_3_41011=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157972\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157973\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012056\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012055\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012060\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012061\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012063\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012058\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012059\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012064\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012065\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24740?source=related_link\">",
"      Desoximetasone: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_3_41012="10-point perceived exertion scale";
var content_f40_3_41012=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F65051&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F65051&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 505px\">",
"   <div class=\"ttl\">",
"    10-point scale of perceived exertion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 485px; height: 680px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Scale reproduced and illustrated with permission from: Borg G. Psychophysical bases of percived exertion. Med Sci Sports Exerc 1982; 14:377.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_3_41012=[""].join("\n");
var outline_f40_3_41012=null;
var title_f40_3_41013="Pyridostigmine: Pediatric drug information";
var content_f40_3_41013=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Pyridostigmine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?26/55/27509?source=see_link\">",
"    see \"Pyridostigmine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?38/53/39764?source=see_link\">",
"    see \"Pyridostigmine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709378\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F215907\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Mestinon&reg;;",
"     </li>",
"     <li>",
"      Mestinon&reg; Timespan&reg;;",
"     </li>",
"     <li>",
"      Regonol&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F215908\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Mestinon&reg;;",
"     </li>",
"     <li>",
"      Mestinon&reg;-SR",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1061685\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antidote, Neuromuscular Blocking Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Cholinergic Agent",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11444893\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Myasthenic syndrome; congenital:",
"     </b>",
"     Limited data available: Oral: 1 mg/kg/dose every 4 hours; maximum daily dose: 7 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     divided in 5-6 doses (Lorenzoni, 2012)",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1061679\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?26/55/27509?source=see_link\">",
"      see \"Pyridostigmine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Infants, Children and Adolescents:",
"     <b>",
"      Note:",
"     </b>",
"     All pediatric dosing recommendations based on immediate release product formulations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Myasthenic syndrome, congenital:",
"     </b>",
"     Limited data available: Oral: 1 mg/kg/dose every 4 hours; maximum daily dose: 7 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     divided in 5-6 doses (Lorenzoni, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Myasthenia gravis, autoimmune:",
"     </b>",
"     Limited data available:",
"     <b>",
"      Note:",
"     </b>",
"     Dosage should be adjusted such that larger doses administered prior to time of greatest fatigue.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Oral: 1 mg/kg/dose every 4-6 hours; maximum daily dose: 7 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     divided in 5-6 doses; usual daily dose: 600 mg/",
"     <b>",
"      day",
"     </b>",
"     ; doses as high as 1500 mg/",
"     <b>",
"      day",
"     </b>",
"     have been used (Andrews, 1998; Maggi, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     I.M., I.V.:  0.05-0.15 mg/kg/dose; maximum  dose: 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Reversal of nondepolarizing neuromuscular blocker:",
"     </b>",
"     Limited data available: I.M., I.V.: 0.1-0.25 mg/kg/dose.",
"     <b>",
"      Note:",
"     </b>",
"     Give atropine or glycopyrrolate immediately prior to minimize side effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Vincristine-induced neurotoxicity:",
"     </b>",
"     Limited data available: Children &ge;2 years and Adolescents: Oral: 3 mg/kg/day divided in 2 doses, given with pyridoxine for 3 weeks; dosing based on a case series of four children (age: 2-13 years) receiving vincristine for treatment of ALL (Akbayram, 2010) and a 2-year old receiving vincristine for a cervical synovial sarcoma (Muller, 2004)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Myasthenia gravis:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Immediate release: Highly individualized dosing ranges: 60-1500 mg/day, usually 600 mg/day divided into 5-6 doses, spaced to provide maximum relief",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Sustained release formulation: Highly individualized dosing ranges: 180-540 mg once or twice daily (doses separated by at least 6 hours);",
"     <b>",
"      Note:",
"     </b>",
"     Most clinicians reserve sustained release dosage form for bedtime dose only.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     I.M. or slow I.V. push: To supplement oral dosage pre- and postoperatively during labor and postpartum, during myasthenic crisis, or when oral therapy is impractical: ~1/30th of oral dose; observe patient closely for cholinergic reactions",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     I.V. infusion: To supplement oral dosage pre- and postoperatively, during labor and postpartum, during myasthenic crisis, or when oral therapy is impractical: Initial: 2 mg/hour with gradual titration in increments of 0.5-1 mg/hour, up to a maximum rate of 4 mg/hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Reversal of nondepolarizing neuromuscular blocker:",
"     </b>",
"     I.V.: 0.1-0.25 mg/kg/dose; 10-20 mg is usually sufficient (full recovery usually occurs &le;15 minutes, but &ge;30 minutes may be required)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Soman nerve gas exposure; pretreatment (military use):",
"     </b>",
"     Oral: 30 mg every 8 hours beginning several hours before exposure; discontinue at first sign of nerve agent exposure, then begin atropine and pralidoxime",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Dosage adjustment in renal impairment:",
"     </b>",
"     There are no dosage adjustments are provided in the manufacturer&rsquo;s labeling; however, lower doses may be required due to prolonged elimination; dosage titration should be based on drug effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosage adjustment in hepatic impairment:",
"     </b>",
"     There are no dosage adjustments are provided in the manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F215882\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as bromide:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Regonol&reg;: 5 mg/mL (2 mL) [contains benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Syrup, oral, as bromide:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mestinon&reg;: 60 mg/5 mL (480 mL) [contains ethanol 5%, sodium benzoate; raspberry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as bromide: 60 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mestinon&reg;: 60 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, sustained release, oral, as bromide:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mestinon&reg; Timespan&reg;: 180 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F215867\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Tablet",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1061689\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Swallow sustained release tablets whole, do not chew or crush",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Parenteral: May administer I.M. or as a direct I.V. slowly over 2-4 minutes; patients receiving large parenteral doses should be pretreated with atropine",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F215955\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Heparin, hydrocortisone sodium succinate, potassium chloride, vitamin B complex with C.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Glycopyrrolate.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1061682\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     All dosage forms: Store at 25&deg;C (77&deg;F), excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); protect from light. Tablets are extremely moisture sensitive; do not remove desiccant and keep bottle closed tightly. Mottling of the Timespan tablets may occur; however, efficacy is not affected.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1061688\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Mestinon&reg;: Treatment of myasthenia gravis (FDA approved in adults); has also been used for treatment of vincristine induced neurotoxicity, congenital myasthenic syndrome, and pretreatment for Soman nerve gas exposure (military use only)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Parenteral: Regonol&reg;: Reversal agent for effects of nondepolarizing neuromuscular blocking agents (FDA approved in adults); has also been used for treatment of myasthenia gravis",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F215957\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Pyridostigmine may be confused with physostigmine",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Regonol&reg; may be confused with Reglan&reg;, Renagel&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F215954\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Arrhythmias (especially bradycardia), AV block, cardiac arrest, decreased carbon monoxide, flushing, hypotension, nodal rhythm, nonspecific ECG changes, syncope, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Convulsions, dizziness, drowsiness, dysphonia, headache, loss of consciousness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Skin rash, thrombophlebitis (I.V.), urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, diarrhea, dysphagia, flatulence, hyperperistalsis, nausea, salivation, stomach cramps, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Urinary urgency",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, dysarthria, fasciculations, muscle cramps, myalgia, spasms, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Amblyopia, lacrimation, small pupils",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Bronchial secretions increased, bronchiolar constriction, bronchospasm, dyspnea, laryngospasm, respiratory arrest, respiratory depression, respiratory muscle paralysis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergic reactions, anaphylaxis, diaphoresis increased",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1061693\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to pyridostigmine, bromides, or any component; GI or GU obstruction",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1061678\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with renal impairment; dosage adjustment may be necessary. Use with caution in patients with seizure disorder, asthma or bronchospastic disease, bradycardia or cardiac arrhythmias, hyperthyroidism, or GI disease, including peptic ulcer. Regonol&reg; injection must be administered by trained personnel",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1061677\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Overdosage may result in cholinergic crisis; this must be distinguished from myasthenic crisis; discontinue if symptoms of excess cholinergic activity (eg, salivation, sweating, urinary incontinence) occur. Adequate facilities should be available for cardiopulmonary resuscitation when testing and adjusting dose for myasthenia gravis; have atropine and epinephrine ready to treat hypersensitivity reactions. For brief or prolonged periods, anticholinesterase insensitivity can develop. Neonates of myasthenic mothers may have transient difficulties in swallowing, sucking, and breathing; use of pyridostigmine may be of benefit; use edrophonium test to assess neonate with these symptoms.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     When used for reversal of muscle relaxants, prior or concurrent doses of atropine or glycopyrrolate should be considered with large doses of pyridostigmine. A peripheral nerve stimulator may be helpful to monitor neuromuscular function and minimize excessive dosing or inadequate reversal.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Some injections contain benzyl alcohol which may cause allergic reactions in susceptible individuals; syrup contains sodium benzoate; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse; use injections containing benzyl alcohol with caution in neonates;",
"     <i>",
"      in vitro",
"     </i>",
"     and animal studies have shown that benzoate, a metabolite of benzyl alcohol, displaces bilirubin from protein binding sites; avoid use of the syrup in neonates",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Pretreatment with pyridostigmine alone will not protect against exposure to Soman nerve gas; its efficacy is dependent upon the rapid use of atropine and pralidoxime after exposure. Discontinue use of pyridostigmine after exposure.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299967\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F215875\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Acetylcholinesterase Inhibitors may enhance the bradycardic effect of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cholinergic Agonists: Acetylcholinesterase Inhibitors may enhance the adverse/toxic effect of Cholinergic Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the adverse/toxic effect of Acetylcholinesterase Inhibitors. Increased muscular weakness may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dipyridamole: May diminish the therapeutic effect of Acetylcholinesterase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methocarbamol: May diminish the therapeutic effect of Pyridostigmine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents (Nondepolarizing): Acetylcholinesterase Inhibitors may diminish the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Succinylcholine: Acetylcholinesterase Inhibitors may increase the serum concentration of Succinylcholine.  Management: Consider alternatives to this combination due to a risk of prolonged neuromuscular blockade.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F16028958\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food delays time to peak serum concentration  by ~90 minutes; AUC unchanged (Aquilonius, 1986).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F215878\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F215891\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Safety has not been established for use during pregnancy. The potential benefit to the mother should outweigh the potential risk to the fetus. When pyridostigmine is needed in myasthenic mothers, giving dose parenterally 1 hour before completion of the second stage of labor may facilitate delivery and protect the neonate during the immediate postnatal state.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1061684\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Muscle strength, heart rate, respiration; vital capacity; observe for cholinergic reactions, particularly when administered I.V.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1061676\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Competitively inhibits destruction of acetylcholine by acetylcholinesterase which facilitates transmission of impulses across myoneural junction producing generalized cholinergic responses such as miosis, increased tonus of skeletal and intestinal musculature, bronchial and ureteral constriction, bradycardia, and increased salivary and sweat gland production",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1061691\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Recovery from vincristine neurotoxicity:  Onset of action: 1-2 weeks (Akbayram, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Myasthenia gravis:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Onset of action:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oral: Within 30 minutes (Maggi, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.M.: 15-30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.V.: Within 2-5 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Duration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oral: 3-4 hours (Maggi, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.M., I.V.: 2-3 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1061692\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Very poor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 0.53-1.76 L/kg (Aquilonius, 1986)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein Binding: None (Aquilonius, 1986)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic and at tissue site by cholinesterases",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Oral: 10% to 20% (Aquilonius, 1986)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: 1-2 hours; renal failure: ~6 hours (Aquilonius, 1986)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Oral: 1-2 hours (Aquilonius, 1986)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Urine (80% to 90% as unchanged drug) (Aquilonius, 1986)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Akbayram S, Akgun C, Do��an M, et al, \"Use of Pyridoxine and Pyridostigmine in Children With Vincristine-Induced Neuropathy,\"",
"      <i>",
"       Indian J Pediatr",
"      </i>",
"      , 2010, 77(6):681-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/3/41013/abstract-text/20532679/pubmed\" id=\"20532679\" target=\"_blank\">",
"        20532679",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Andrews PI, \"A Treatment Algorithm for Autoimmune Myasthenia Gravis in Childhood,\"",
"      <i>",
"       Ann N Y Acad Sci",
"      </i>",
"      , 1998, 841:789-802.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/3/41013/abstract-text/9668332/pubmed\" id=\"9668332\" target=\"_blank\">",
"        9668332",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aquilonius SM and Hartvig P, \"Clinical Pharmacokinetics of Cholinesterase Inhibitors,\"",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1986, 11(3):236-49.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/3/41013/abstract-text/3524957/pubmed\" id=\"3524957\" target=\"_blank\">",
"        3524957",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lorenzoni PJ, Scola RH, Kay CS, et al, \"Congenital Myasthenic Syndrome: A Brief Review,\"",
"      <i>",
"       Pediatr Neurol",
"      </i>",
"      , 2012, 46(3):141-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/3/41013/abstract-text/22353287/pubmed\" id=\"22353287\" target=\"_blank\">",
"        22353287",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Maggi L and Mantegazza R, \"Treatment of Myasthenia Gravis: Focus on Pyridostigmine,\"",
"      <i>",
"       Clin Drug Investig",
"      </i>",
"      , 2011, 31(10):691-701.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/3/41013/abstract-text/21815707/pubmed\" id=\"21815707\" target=\"_blank\">",
"        21815707",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      M&uuml;ller L, Kramm CM, Tenenbaum T, et al, \"Treatment of Vincristine-Induced Bilateral Ptosis With Pyridoxine and Pyridostigmine,\"",
"      <i>",
"       Pediatr Blood Cancer",
"      </i>",
"      , 2004, 42(3):287-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/3/41013/abstract-text/14752870/pubmed\" id=\"14752870\" target=\"_blank\">",
"        14752870",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12752 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-06EB330AA9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_3_41013=[""].join("\n");
var outline_f40_3_41013=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709378\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215907\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215908\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061685\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11444893\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061679\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215882\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215867\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061689\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215955\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061682\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061688\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215957\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215954\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061693\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061678\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061677\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299967\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215875\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16028958\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215878\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215891\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061684\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061676\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061691\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061692\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12752\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12752|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?26/55/27509?source=related_link\">",
"      Pyridostigmine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?38/53/39764?source=related_link\">",
"      Pyridostigmine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_3_41014="Coarcation of the aorta anatomy";
var content_f40_3_41014=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F62095&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F62095&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 570px\">",
"   <div class=\"ttl\">",
"    Coarcation of the aorta anatomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 550px; height: 442px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Coarcation of the aorta with severe obstruction of blood flow to the descending thoracic aorta. The descending aorta is supplied by collaterals from the internal thoracic intercostal, subclavian, and scapular arteries.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Wolters Kluwer. Copyright &copy; 2008.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_3_41014=[""].join("\n");
var outline_f40_3_41014=null;
var title_f40_3_41015="Acquired ichthyosis 1";
var content_f40_3_41015=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F57819%7EONC%2F64680&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F57819%7EONC%2F64680&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Acquired ichthyosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 402px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Adherent, \"fish-like\" scales are present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 492px\">",
"   <div class=\"ttl\">",
"    Acquired ichthyosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 472px; height: 217px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Severe scaling of the skin with hyperkeratosis involving the skin of the upper thigh (panel A) and soles of the feet (panel B) in a patient with Hodgkins disease.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Rizos, E, Milionis, RH, Pavlidis, N Elisaf, MS. Acquired icthyosis: A paraneoplastic skin manifestation of Hodgkin's disease. The Lancet-Oncology 2002; 3:727. Copyright 2002 Elsevier Science.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_3_41015=[""].join("\n");
var outline_f40_3_41015=null;
var title_f40_3_41016="Post-exposure prophylaxis against varicella-zoster virus infection";
var content_f40_3_41016=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Post-exposure prophylaxis against varicella-zoster virus infection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/3/41016/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/3/41016/contributors\">",
"     Mary A Albrecht, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/3/41016/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/3/41016/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/3/41016/contributors\">",
"     Morven S Edwards, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/3/41016/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/3/41016/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/3/41016/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 8, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Varicella-zoster virus (VZV) is one of eight herpesviruses known to cause human infection and is found worldwide. Primary infection with VZV causes chickenpox, with fever and a characteristic vesicular rash. Although varicella is usually a mild, self-limited illness, it can be associated with complications, such as pneumonia, hepatitis, encephalitis, and secondary bacterial infection. Complicated infection can lead to morbidity and mortality, particularly among immunocompromised hosts and pregnant women.",
"   </p>",
"   <p>",
"    This topic will address the use of active immunization (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/28/4551?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    ) and passive immunization (VariZIG) and other interventions for post-exposure prophylaxis in nonimmune individuals. The efficacy and safety of the varicella vaccine for routine immunization in children and adults are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/26/37289?source=see_link\">",
"     \"Prevention of varicella-zoster virus infection: Chickenpox\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Post-exposure prophylaxis for neonates, pregnant women, bone marrow transplant recipients, and health care workers is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/11/4278?source=see_link\">",
"     \"Varicella-zoster infection in the newborn\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/28/33225?source=see_link\">",
"     \"Varicella-zoster virus infection in pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/28/32200?source=see_link\">",
"     \"Prevention and control of varicella in hospitals\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/57/25498?source=see_link\">",
"     \"Immunizations after hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical manifestations and management of varicella are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/44/33480?source=see_link\">",
"     \"Clinical features of varicella-zoster virus infection: Chickenpox\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/11/4278?source=see_link\">",
"     \"Varicella-zoster infection in the newborn\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/36/23110?source=see_link\">",
"     \"Treatment of varicella-zoster virus infection: Chickenpox\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H878311\">",
"    <span class=\"h1\">",
"     GENERAL BACKGROUND",
"    </span>",
"    &nbsp;&mdash;&nbsp;VZV infection causes two clinically distinct forms of disease: varicella (chickenpox) and herpes zoster (shingles).",
"   </p>",
"   <p>",
"    Primary VZV infection results in the diffuse vesicular rash of varicella, which typically results in lifetime immunity. In healthy persons, reinfection with VZV is rare [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41016/abstract/1\">",
"     1",
"    </a>",
"    ]. Primary varicella is associated with significant morbidity and mortality in adults and immunocompromised hosts. Since the introduction of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/28/4551?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    in 1995, there have been substantial declines in morbidity and mortality secondary to complicated varicella infection in the United States and Europe. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/26/37289?source=see_link&amp;anchor=H30#H30\">",
"     \"Prevention of varicella-zoster virus infection: Chickenpox\", section on 'Vaccine programs in the United States'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Endogenous reactivation of latent VZV typically results in a localized skin infection in a dermatomal distribution, known as herpes zoster (ie, shingles). Herpes zoster is more commonly seen in older adults (greater than 60) and immunocompromised hosts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H878525\">",
"    <span class=\"h1\">",
"     TRANSMISSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, the risk of transmission of VZV infection is higher with exposure to persons with primary varicella compared to herpes zoster. The period of contagiousness during primary varicella is estimated to begin approximately 1 to 2 days before the onset of rash. Persons with either illness are not infectious once the lesions have crusted over.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H878532\">",
"    <span class=\"h2\">",
"     Person to person",
"    </span>",
"    &nbsp;&mdash;&nbsp;VZV is highly communicable during primary varicella, with secondary attack rates in susceptible household contacts greater than 90 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41016/abstract/1\">",
"     1",
"    </a>",
"    ]. VZV is usually transmitted by infected secretions harbored in the nasopharyngeal mucosa via droplets deposited onto the mucosal surfaces of the conjunctiva or",
"    <span class=\"nowrap\">",
"     nasal/oral",
"    </span>",
"    passages. Other mechanisms include direct contact with vesicular fluids that contain virus or, rarely, through the airborne spread of virus.",
"   </p>",
"   <p>",
"    Susceptible persons can also acquire VZV infection from exposure to persons with zoster, although the transmission rates are considerably lower and usually require close exposure to open cutaneous lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41016/abstract/2\">",
"     2",
"    </a>",
"    ]. Suspected airborne transmission of VZV during zoster has been reported rarely in nosocomial settings. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/28/32200?source=see_link&amp;anchor=H8#H8\">",
"     \"Prevention and control of varicella in hospitals\", section on 'Transmission from persons with zoster'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H878571\">",
"    <span class=\"h2\">",
"     Mother to child",
"    </span>",
"    &nbsp;&mdash;&nbsp;Issues related to transmission of VZV infection during pregnancy are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/28/33225?source=see_link\">",
"     \"Varicella-zoster virus infection in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H878751\">",
"    <span class=\"h1\">",
"     INCUBATION PERIOD",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incubation period of varicella in an adult or child is 10 to 21 days after exposure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ASSESSMENT OF RISK OF INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Factors to consider prior to providing post-exposure prophylaxis include assessment of the risk of serious disease for the exposed individual, the nature of the exposure event, and the patient&rsquo;s susceptibility to VZV infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41016/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H879120\">",
"    <span class=\"h2\">",
"     Determining susceptibility",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Advisory Committee on Immunization Practices (ACIP) has suggested that the following criteria should be used for evidence of immunity to varicella [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41016/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Written documentation of varicella vaccination",
"     </li>",
"     <li>",
"      Prior laboratory evidence of immunity",
"     </li>",
"     <li>",
"      Birth in the United States before 1980",
"     </li>",
"     <li>",
"      Prior diagnosis of varicella or herpes zoster illness by a health care provider",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Self-reporting of past varicella infection by adults is considered valid evidence of immunity based on epidemiologic studies showing an excellent correlation between clinical history of varicella infection with VZV-specific antibodies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41016/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Adults born before 1980 are generally considered immune. In addition, only 10 to 30 percent of adults with a negative or uncertain history of varicella are found to be VZV seronegative [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41016/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, a history of varicella infection among young children is not a reliable indicator of past disease. In a cross-sectional serologic survey performed between 2004 and 2006, unvaccinated children were evaluated for a prior history of varicella infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41016/abstract/6\">",
"     6",
"    </a>",
"    ]. A history of childhood varicella was not predictive of seropositivity among those born after 1994, while a history of clinical disease remained highly predictive of seropositivity among adolescents and young adults (&gt;99 percent positive predictive value). The ACIP recommends that evidence of varicella immunity in children should be established by the healthcare provider (through prior diagnosis by the physician or documentation in the medical record).",
"   </p>",
"   <p>",
"    Full term infants often have protective maternal antibodies until at least six months of age. The management of the newborn with varicella exposure is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/11/4278?source=see_link&amp;anchor=H6#H6\">",
"     \"Varicella-zoster infection in the newborn\", section on 'Management of exposure'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H879579\">",
"    <span class=\"h2\">",
"     Types of exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of VZV infection in a susceptible person varies by the duration and nature of the exposure. All of the following should be considered events with potential risk:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Indoor face-to-face contact with a person with varicella",
"     </li>",
"     <li>",
"      Close contact with a person with herpes zoster",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Varicella is very contagious. Some experts consider exposures of more than five minutes of concern, while others contend that only those with more than one hour of contact are significant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41016/abstract/1,7\">",
"     1,7",
"    </a>",
"    ]. However, there is general agreement that those with the greatest risk of exposure are household contacts where transmission rates are &gt;90 percent.",
"   </p>",
"   <p>",
"    Transmission of localized VZV from a patient with herpes zoster is uncommon, but may occur within households with sustained exposure to open lesions. Persons with herpes zoster should be instructed to keep lesions covered, whenever possible, to decrease the risk of environmental contamination with VZV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41016/abstract/8\">",
"     8",
"    </a>",
"    ]. The risk of viral shedding in the environment was shown to be lower with use of an occlusive dressing compared to standard gauze bandages [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41016/abstract/9\">",
"     9",
"    </a>",
"    ]. The risk of VZV transmission is higher among patients with disseminated zoster.",
"    <br/>",
"    <br/>",
"    Rare transmission of VZV infection from a patient with localized herpes zoster has occurred without direct contact (presumably through airborne transmission) in the nosocomial setting. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/28/32200?source=see_link&amp;anchor=H8#H8\">",
"     \"Prevention and control of varicella in hospitals\", section on 'Transmission from persons with zoster'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H879742\">",
"    <span class=\"h2\">",
"     Role of serologic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serologic testing is cost-effective and should be performed, if feasible. However, laboratory turnaround time often prohibits testing prior to timely preventive interventions (see",
"    <a class=\"local\" href=\"#H8\">",
"     'Testing for seroconversion'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H929667\">",
"    <span class=\"h1\">",
"     TYPES OF POSTEXPOSURE PROPHYLAXIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether active immunization (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/28/4551?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    ) or passive immunization (varicella specific antibodies) is offered to a susceptible person with a history of varicella exposure will depend on the host.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H929999\">",
"    <span class=\"h2\">",
"     Who is eligible for varicella vaccine?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Active immunization with the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/28/4551?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    within three to five days of exposure is associated with both prevention of infection among susceptible persons and lessening of disease severity in those who do become ill [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41016/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/28/4551?source=see_link\">",
"     Varicella vaccine",
"    </a>",
"    is recommended by the ACIP for healthy, but susceptible adults and children who were exposed to varicella, who have not received the full two-dose series. Small case series have demonstrated that varicella vaccine is efficacious for postexposure prophylaxis among household contacts of index varicella cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41016/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. In one report, 18 susceptible contacts were vaccinated within three days of exposure and 19 contacts who did not receive any intervention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41016/abstract/12\">",
"     12",
"    </a>",
"    ]. Clinical varicella occurred in all of the controls and in none of the vaccinated subjects.",
"   </p>",
"   <p>",
"    Although most studies on the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/28/4551?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    for postexposure prophylaxis have been done in children, susceptible adults should also be offered immunization, particularly in light of the elevated risk of complicated infection in this population.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H929793\">",
"    <span class=\"h2\">",
"     Which patients require passive immunoprophylaxis?",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/28/4551?source=see_link\">",
"     Varicella vaccine",
"    </a>",
"    , which contains live attenuated virus, is generally contraindicated for immunocompromised hosts, including those receiving immunosuppressive medications. Patients with altered immunity, who cannot receive varicella vaccination, are eligible for passive immunization (eg, VariZIG). The efficacy of VariZIG is discussed below. (see",
"    <a class=\"local\" href=\"#H9\">",
"     'Passive immunization'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    The ACIP recommends that the following patient groups receive immunoprophylaxis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41016/abstract/1,14\">",
"     1,14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Immunocompromised patients (including those with primary and acquired immunodeficiencies)",
"     </li>",
"     <li>",
"      Persons with neoplastic disease",
"     </li>",
"     <li>",
"      Persons taking immunosuppressive therapies",
"     </li>",
"     <li>",
"      Neonates",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, because the effects of the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/28/4551?source=see_link\">",
"     varicella virus vaccine",
"    </a>",
"    on the fetus are unknown, pregnant women should not be vaccinated. Passive immunoprophylaxis should be used when postexposure prophylaxis is indicated in a pregnant female. Management of varicella exposure during pregnancy is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/28/33225?source=see_link&amp;anchor=H24974620#H24974620\">",
"     \"Varicella-zoster virus infection in pregnancy\", section on 'Post-exposure prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Passive immunoprophylaxis is not indicated in a patient with a history of two prior doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/28/4551?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    that preceded the onset of immunocompromise.",
"   </p>",
"   <p>",
"    The management of the pregnant female or newborn with a history of varicella exposure is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/28/33225?source=see_link\">",
"     \"Varicella-zoster virus infection in pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/11/4278?source=see_link\">",
"     \"Varicella-zoster infection in the newborn\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     EFFICACY OF IMMUNIZATION DURING OUTBREAKS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Varicella vaccination is recommended by the ACIP for control of varicella outbreaks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41016/abstract/1,15,16\">",
"     1,15,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The efficacy of varicella immunization in containing transmission was assessed in a retrospective investigation of a varicella outbreak in 1996 (soon after the licensure of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/28/4551?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41016/abstract/16\">",
"     16",
"    </a>",
"    ]. Of all the children enrolled in a day care center, 148 children were considered susceptible due to absence of prior immunization or history of varicella; 66 (45 percent) had previously received the vaccine. No serologic testing was performed. The following results were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The frequency of varicella infection was significantly reduced in vaccinated compared with unvaccinated children (14 versus 88 percent).",
"     </li>",
"     <li>",
"      When infection did occur, the clinical illness was less severe in vaccinated children and resulted in fewer days of absence from the day care center.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/28/4551?source=see_link\">",
"       Varicella vaccine",
"      </a>",
"      was estimated to be 86 percent effective against all forms of disease and 100 percent effective against moderate to severe disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In response to an outbreak, children who have only received one dose of vaccine prior to exposure should receive a second dose, provided that three months have elapsed since the first dose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41016/abstract/1\">",
"     1",
"    </a>",
"    ]. Persons who are vaccinated for the purpose of postexposure prophylaxis can return to school immediately [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41016/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H880069\">",
"    <span class=\"h1\">",
"     VARICELLA VACCINE ADMINISTRATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H929977\">",
"    <span class=\"h2\">",
"     Available formulations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two live attenuated varicella virus vaccines are available for prevention of varicella: single antigen",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/28/4551?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    (VARIVAX) and combination MMRV vaccine (ProQuad). The dosing and adverse events associated with these formulations are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/26/37289?source=see_link\">",
"     \"Prevention of varicella-zoster virus infection: Chickenpox\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most studies of postexposure prophylaxis have utilized the single antigen vaccine (ie, Varivax). There are no comparable data on the use of the quadrivalent vaccine (MMRV; ProQuad).",
"   </p>",
"   <p>",
"    The",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/28/4551?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    should be administered ideally within three days of exposure to chickenpox, although immunizations have been effective even if given within a five-day period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41016/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H879156\">",
"    <span class=\"h2\">",
"     Adverse events",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/28/4551?source=see_link\">",
"     Varicella vaccine",
"    </a>",
"    is generally well tolerated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/26/37289?source=see_link&amp;anchor=H23#H23\">",
"     \"Prevention of varicella-zoster virus infection: Chickenpox\", section on 'Adverse events'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Testing for seroconversion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serologic testing after immunization is unnecessary since seroconversion rates are very high [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41016/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H930074\">",
"    <span class=\"h2\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Information about contraindications for vaccine administration and adverse events are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/26/37289?source=see_link\">",
"     \"Prevention of varicella-zoster virus infection: Chickenpox\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PASSIVE IMMUNIZATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main choice for passive immunization against varicella infection is currently VariZIG. From a historical perspective, the efficacy of passive immunization was first noted several decades ago.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8196054\">",
"    <span class=\"h2\">",
"     General background",
"    </span>",
"    &nbsp;&mdash;&nbsp;In several small case series, immunoglobulin products have reduced attack rates after exposure to varicella infection and modulated the expression of disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41016/abstract/18\">",
"     18",
"    </a>",
"    ]. However, patients need further follow-up to determine if immunoprophylaxis was effective since 20 to 30 percent of patients may still develop infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41016/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    The true efficacy of immunoprophylaxis is somewhat difficult to discern. Most studies of immunoprophylaxis have not included a placebo arm so efficacy is inferred from historical data, which demonstrate transmission rates of greater than 90 percent after household exposure to VZV infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41016/abstract/18,21-23\">",
"     18,21-23",
"    </a>",
"    ]. Furthermore, results of very early trials are difficult to interpret since diagnostic antibody testing for true VZV susceptibility was not as sensitive as currently used methodologic testing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41016/abstract/18,24\">",
"     18,24",
"    </a>",
"    ]. Passive immunization is generally used after VZV exposure in patients who are not candidates for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/28/4551?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    . (See",
"    <a class=\"local\" href=\"#H929793\">",
"     'Which patients require passive immunoprophylaxis?'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H234145\">",
"    <span class=\"h2\">",
"     Historical perspective",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the 1960s, there was interest in preventing varicella infection with the use of human serum immunoglobulin (ISG) as passive immunization. Although ISG did not decrease varicella transmission, it did appear to ameliorate disease severity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41016/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Subsequently, there was interest in producing immunoglobulin products with high titers of VZV specific antibodies using plasma from persons recovering from herpes zoster infection or from volunteer blood donors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41016/abstract/18\">",
"     18",
"    </a>",
"    ]. Products used in the past included zoster immune globulin (ZIG) and varicella-zoster immune globulin (VZIG); neither is currently available. Immunoglobulin products with higher antibody titers are associated with lower varicella attack rates among nonimmune exposed persons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41016/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the United States, VariZIG is currently used for postexposure prophylaxis against varicella-zoster virus; limited data suggest similar efficacy rates of VariZIG compared to VZIG, as discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H234101\">",
"    <span class=\"h3\">",
"     Zoster immune globulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;A small landmark study from 1969 verified the proof-of-concept that passive immunization with high titers of VZV antibodies may protect against acquisition of varicella infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41016/abstract/18\">",
"     18",
"    </a>",
"    ]. In a small study of six households where one child developed clinical varicella, one sibling was given zoster immune globulin (ZIG) while the other sibling received human immune serum globulin (ISG) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41016/abstract/18\">",
"     18",
"    </a>",
"    ]. None of the six ZIG recipients developed disease whereas all of the other six recipients of ISG developed varicella infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Varicella zoster immune globulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Small clinical studies with varicella-zoster immunoglobulin (VZIG) demonstrated that passive immunization in both normal hosts and immunocompromised patients led to significantly lower than expected attack rates after varicella exposure compared with historical controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41016/abstract/18,21-23\">",
"     18,21-23",
"    </a>",
"    ]. Passive immunization also modulated disease severity in those who did become infected (eg, fewer lesions) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41016/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some recipients of VZIG developed asymptomatic seroconversion, which is uncommonly seen among untreated hosts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41016/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/44/33480?source=see_link\">",
"     \"Clinical features of varicella-zoster virus infection: Chickenpox\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     VariZIG",
"    </span>",
"    &nbsp;&mdash;&nbsp;VariZIG (Cangene Corporation, Winnipeg, Canada) is a purified human immune globulin preparation made from plasma containing high levels of anti-varicella antibodies (IgG) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41016/abstract/26\">",
"     26",
"    </a>",
"    ]. During preparation, VariZIG undergoes filtration and inactivation to decrease the transmission of known viruses such as HIV and hepatitis viruses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H233733\">",
"    <span class=\"h3\">",
"     Clinical data",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are limited clinical data regarding the efficacy of VariZIG. In a study of 60 pregnant females with varicella exposure, patients were randomly assigned to either VZIG or VariZIG based on time from exposure (ie, 1 to 4 days or 5 to 10 days) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41016/abstract/20\">",
"     20",
"    </a>",
"    ]. Patients who were exposed to varicella more than 14 days earlier were excluded from the trial. The efficacy and safety of the two products were similar over the 28-day period of follow-up; 29 percent developed varicella in the VariZIG group compared to 42 percent in the VZIG arm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41016/abstract/20\">",
"     20",
"    </a>",
"    ]. The duration following varicella exposure to the intervention did not affect efficacy.",
"   </p>",
"   <p>",
"    There are no published data regarding the efficacy of VariZIG in the prevention of varicella infection in hematopoietic stem cell transplant recipients or in HIV-infected patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H151737850\">",
"    <span class=\"h3\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;In accordance with the United States Advisory Committee on Immunization Practices, we recommend immunoprophylaxis with VariZIG after VZV exposure for the following patients who are at high risk for severe infection and complications and who are not candidates for the VZV vaccine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41016/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Immunocompromised children and adults who lack evidence of immunity to VZV",
"     </li>",
"     <li>",
"      Newborns of mothers with varicella shortly before or after delivery (ie, five days before to two days after delivery)",
"     </li>",
"     <li>",
"      Premature infants born at &ge;28 weeks of gestation who are exposed during the neonatal period and whose mothers do not have evidence of immunity",
"     </li>",
"     <li>",
"      Premature infants born at &lt;28 weeks of gestation or who weigh &le;1000 g at birth and were exposed during the neonatal period, regardless of their mothers' evidence of immunity status",
"     </li>",
"     <li>",
"      Pregnant women who lack evidence of immunity to VZV",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In 2012, the US Food and Drug Administration (FDA) approved VariZIG following exposure to VZV to reduce the severity of VZV infection for the groups described above as well as for immunocompetent adults who lack evidence of immunity to VZV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41016/abstract/27,29\">",
"     27,29",
"    </a>",
"    ]. Prior to its approval, VariZIG was available via an expanded access protocol.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8196144\">",
"    <span class=\"h3\">",
"     Time interval from exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the past, passive immunization was recommended within four days of exposure to varicella. However, limited data suggest that the incidence of varicella is comparable among persons who receive passive immunization within four days of varicella exposure or within 5 to 10 days of exposure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41016/abstract/20,30\">",
"     20,30",
"    </a>",
"    ]. Based on these data, the Food and Drug Administration (FDA) has extended the window of passive immunization after varicella exposure from 4 to 10 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41016/abstract/28\">",
"     28",
"    </a>",
"    ]. When postexposure prophylaxis is indicated, passive immunization with VariZIG should be offered as soon as possible. (See",
"    <a class=\"local\" href=\"#H8196327\">",
"     'Intravenous immune globulin (IVIG)'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21573970\">",
"    <span class=\"h3\">",
"     How to administer",
"    </span>",
"    &nbsp;&mdash;&nbsp;The recommended dose is 125",
"    <span class=\"nowrap\">",
"     units/10",
"    </span>",
"    kg body weight, up to a maximum of 625 units (five vials); the minimum dose is 125",
"    <span class=\"nowrap\">",
"     units/vial.",
"    </span>",
"    VariZIG is lyophilized and must be reconstituted for intramuscular or intravenous administration. Details on the administration of VariZIG are found elsewhere. (See",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/8/8326?source=see_link\">",
"     \"Varicella-zoster immune globulin (human): Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Any patient who receives VariZIG should also receive",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/28/4551?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    , provided vaccine is not contraindicated (eg, pregnant females). Varicella vaccine should be delayed until five months after receipt of VariZIG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41016/abstract/26\">",
"     26",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8196327\">",
"    <span class=\"h2\">",
"     Intravenous immune globulin (IVIG)",
"    </span>",
"    &nbsp;&mdash;&nbsp;If VariZIG cannot be obtained, then intravenous immunoglobulin (IVIG) should be considered [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41016/abstract/1\">",
"     1",
"    </a>",
"    ]. IVIG contains anti-varicella antibody titers that vary from lot to lot. The recommended dose for varicella prophylaxis is 400",
"    <span class=\"nowrap\">",
"     mg/kg,",
"    </span>",
"    administered once. Limited data exist regarding efficacy.",
"   </p>",
"   <p>",
"    The duration of protection is unknown but expected to be at least three weeks. As noted above with VariZIG, IVIG might extend the incubation period of the virus from 10 to 21 days to &ge;28 days, so clinical follow-up for signs and symptoms of infection is indicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Monitoring for infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should be monitored for varicella for 28 days after exposure since immunoprophylaxis may prolong the incubation period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41016/abstract/23,31\">",
"     23,31",
"    </a>",
"    ]. Any immunocompromised patient who develops signs and symptoms of varicella infection should receive prompt therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    or a related antiviral drug. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/36/23110?source=see_link\">",
"     \"Treatment of varicella-zoster virus infection: Chickenpox\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     ACYCLOVIR FOR POSTEXPOSURE PROPHYLAXIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H878965\">",
"    <span class=\"h2\">",
"     Healthy children and adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     Acyclovir",
"    </a>",
"    is not indicated for routine pre-emptive use among susceptible healthy children, adolescents, or adults after exposure to varicella [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41016/abstract/1\">",
"     1",
"    </a>",
"    ]. Varicella immunization is preferred for postexposure prophylaxis among healthy susceptible persons. (See",
"    <a class=\"local\" href=\"#H929667\">",
"     'Types of postexposure prophylaxis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    One small nonrandomized study in 50 Japanese children evaluated the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    for the prevention of varicella after household exposure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41016/abstract/32\">",
"     32",
"    </a>",
"    ]. The study design compared placebo with acyclovir (40 or 80",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    daily in four divided doses) given on days seven to nine after exposure and continued for seven days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41016/abstract/32\">",
"     32",
"    </a>",
"    ]. Varicella developed in fewer of those treated with acyclovir (16 versus 100 percent); the incidence of fever and severity of skin lesions was also reduced in the acyclovir-treated children who did experience infection. However, the conclusions of the study are limited by the small sample size and the design of the study.",
"   </p>",
"   <p>",
"    There are no randomized studies regarding the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    in adults, since this is a less common disease among this age group, even prior to the availability of immunization. Healthy adults who have been exposed to varicella should be immunized with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/28/4551?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    which is effective in prevention of infection after exposure and affords long-lasting protection. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Immunocompromised hosts",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no studies of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    in immunocompromised hosts after varicella exposure. The ACIP, the Centers for Disease Control (CDC), and the HIV Medicine Association recommend VariZIG for immunocompromised patients who have been exposed to varicella [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41016/abstract/1,33\">",
"     1,33",
"    </a>",
"    ]. The management of immunocompromised patients is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/57/25498?source=see_link\">",
"     \"Immunizations after hematopoietic cell transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/48/23306?source=see_link&amp;anchor=H20#H20\">",
"     \"Immunizations in solid organ transplant candidates and recipients\", section on 'Post-exposure prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H879052\">",
"    <span class=\"h2\">",
"     Pregnant females",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunoprophylaxis (ie, VariZIG) is recommended for susceptible pregnant females who have been exposed to varicella infection. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/28/33225?source=see_link&amp;anchor=H18#H18\">",
"     \"Varicella-zoster virus infection in pregnancy\", section on 'Management of maternal VZV infection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H879861\">",
"    <span class=\"h1\">",
"     WHAT TO DO WHEN PROPHYLAXIS FAILS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Persons who develop clinical symptoms despite active or passive immunization should be treated rapidly with antiviral therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/36/23110?source=see_link\">",
"     \"Treatment of varicella-zoster virus infection: Chickenpox\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/25/39318?source=see_link\">",
"       \"Patient information: Adult vaccines (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?36/18/37156?source=see_link\">",
"       \"Patient information: Vaccines for children age 7 to 18 years (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?2/40/2691?source=see_link\">",
"       \"Patient information: Chickenpox prevention and treatment (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary infection with varicella-zoster virus (VZV) causes chickenpox, with fever and a characteristic vesicular rash. Although varicella is usually a mild, self-limited illness, it can be associated with morbidity and mortality, particularly among immunocompromised hosts and pregnant women. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      VZV infection causes two clinically distinct forms of disease: varicella (chickenpox) and herpes zoster (shingles). (See",
"      <a class=\"local\" href=\"#H878311\">",
"       'General background'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In general, the risk of transmission of VZV infection is higher after exposure to persons with primary varicella compared with herpes zoster. The period of contagiousness is estimated to begin approximately one to two days before the onset of rash during primary varicella. Persons with either illness are not infectious once the lesions have crusted over. (See",
"      <a class=\"local\" href=\"#H878525\">",
"       'Transmission'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Essential factors to consider prior to providing post-exposure prophylaxis include assessment of the exposure itself, risk of severe infection, and the patient&rsquo;s susceptibility to VZV infection. Evidence of immunity can include written documentation of vaccination, prior laboratory evidence of immunity, birth in the United States before 1980, or a prior diagnosis of varicella or herpes zoster illness by a health care provider. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Assessment of risk of infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Whether active immunization (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/28/4551?source=see_link\">",
"       varicella vaccine",
"      </a>",
"      ) or passive immunization (varicella specific antibodies; VariZIG) is offered to a susceptible person with a history of varicella exposure will depend on the host. Varicella vaccine, which contains live attenuated virus, should not be given to patients with altered immunity. (See",
"      <a class=\"local\" href=\"#H929667\">",
"       'Types of postexposure prophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Immunization with the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/28/4551?source=see_link\">",
"       varicella vaccine",
"      </a>",
"      is associated with both prevention of infection among susceptible persons and lessening of disease severity in those who do become infected. We recommend varicella vaccine for postexposure prophylaxis in healthy VZV-nonimmune children and adults (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Persons who have a history of only one dose of vaccine should be offered a second dose of vaccine for completion of their series, as long as three months have passed since their first dose. (See",
"      <a class=\"local\" href=\"#H929667\">",
"       'Types of postexposure prophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend immunoprophylaxis with VariZIG after VZV exposure for patients who are not candidates for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/28/4551?source=see_link\">",
"       varicella vaccine",
"      </a>",
"      (eg, pregnant women, infants, and immunocompromised patients) (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'VariZIG'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When indicated, VariZIG should be administered as soon as possible. The efficacy of VariZIG has only been studied within 10 days of varicella exposure; the efficacy of passive immunization after this time interval is unknown. (See",
"      <a class=\"local\" href=\"#H8196144\">",
"       'Time interval from exposure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who receive VariZIG for post-exposure prophylaxis should be monitored for varicella for 28 days after exposure since passive immunization may prolong the incubation period. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Passive immunization'",
"      </a>",
"      above.) Patients who develop varicella infection despite prophylaxis should be treated with antiviral therapy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/36/23110?source=see_link\">",
"       \"Treatment of varicella-zoster virus infection: Chickenpox\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Any patient who receives VariZIG should also receive",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/28/4551?source=see_link\">",
"       varicella vaccine",
"      </a>",
"      , provided vaccine is not contraindicated (eg, pregnant females, immunocompromised hosts). Varicella vaccine should be delayed until five months after receipt of VariZIG. (See",
"      <a class=\"local\" href=\"#H21573970\">",
"       'How to administer'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/3/41016/abstract/1\">",
"      Marin M, G&uuml;ris D, Chaves SS, et al. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007; 56:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/3/41016/abstract/2\">",
"      VariZIG for prophylaxis after exposure to varicella. Med Lett Drugs Ther 2006; 48:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/3/41016/abstract/3\">",
"      Marin M, Watson TL, Chaves SS, et al. Varicella among adults: data from an active surveillance project, 1995-2005. J Infect Dis 2008; 197 Suppl 2:S94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/3/41016/abstract/4\">",
"      Struewing JP, Hyams KC, Tueller JE, Gray GC. The risk of measles, mumps, and varicella among young adults: a serosurvey of US Navy and Marine Corps recruits. Am J Public Health 1993; 83:1717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/3/41016/abstract/5\">",
"      Centers for Disease Control and Prevention (CDC). Varicella-related deaths among adults--United States, 1997. MMWR Morb Mortal Wkly Rep 1997; 46:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/3/41016/abstract/6\">",
"      Perella D, Fiks AG, Jumaan A, et al. Validity of reported varicella history as a marker for varicella zoster virus immunity among unvaccinated children, adolescents, and young adults in the post-vaccine licensure era. Pediatrics 2009; 123:e820.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Varicella-zoster infections. In: Red Book: 2006 Report of the Committee on Infectious Diseases, 27th ed, Pickering LK (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2006. p.711.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/3/41016/abstract/8\">",
"      Breuer J. Herpes zoster: new insights provide an important wake-up call for management of nosocomial transmission. J Infect Dis 2008; 197:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/3/41016/abstract/9\">",
"      Suzuki K, Yoshikawa T, Tomitaka A, et al. Detection of aerosolized varicella-zoster virus DNA in patients with localized herpes zoster. J Infect Dis 2004; 189:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/3/41016/abstract/10\">",
"      Centers for Disease Control and Prevention (CDC). Global Disease Elimination and Eradication as Public Health Strategies. Proceedings of a conference. Atlanta, Georgia, USA. 23-25 February 1998. . MMWR Morb Mortal Wkly Rep 1999; 48 Suppl:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/3/41016/abstract/11\">",
"      Salzman MB, Garcia C. Postexposure varicella vaccination in siblings of children with active varicella. Pediatr Infect Dis J 1998; 17:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/3/41016/abstract/12\">",
"      Asano Y, Nakayama H, Yazaki T, et al. Protection against varicella in family contacts by immediate inoculation with live varicella vaccine. Pediatrics 1977; 59:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/3/41016/abstract/13\">",
"      Macartney K, McIntyre P. Vaccines for post-exposure prophylaxis against varicella (chickenpox) in children and adults. Cochrane Database Syst Rev 2008; :CD001833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/3/41016/abstract/14\">",
"      Masur H, Kaplan JE, Holmes KK, et al. Guidelines for preventing opportunistic infections among HIV-infected persons--2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. Ann Intern Med 2002; 137:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/3/41016/abstract/15\">",
"      Haddad MB, Hill MB, Pavia AT, et al. Vaccine effectiveness during a varicella outbreak among schoolchildren: Utah, 2002-2003. Pediatrics 2005; 115:1488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/3/41016/abstract/16\">",
"      Izurieta HS, Strebel PM, Blake PA. Postlicensure effectiveness of varicella vaccine during an outbreak in a child care center. JAMA 1997; 278:1495.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Committee on Infectious Diseases. Varicella vaccine update. Pediatrics 2000; 105:136. (Updated May 16, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/3/41016/abstract/18\">",
"      Brunell PA, Ross A, Miller LH, Kuo B. Prevention of varicella by zoster immune globulin. N Engl J Med 1969; 280:1191.",
"     </a>",
"    </li>",
"    <li>",
"     Levin M, Nelson W, Preblud S, et al. Clinical Trials With Varicella-Zoster Immunoglobulins, Academic Press Inc., Ltd, London 1986. p.255.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/3/41016/abstract/20\">",
"      Koren G, Money D, Boucher M, et al. Serum concentrations, efficacy, and safety of a new, intravenously administered varicella zoster immune globulin in pregnant women. J Clin Pharmacol 2002; 42:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/3/41016/abstract/21\">",
"      Zaia JA, Levin MJ, Preblud SR, et al. Evaluation of varicella-zoster immune globulin: protection of immunosuppressed children after household exposure to varicella. J Infect Dis 1983; 147:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/3/41016/abstract/22\">",
"      Gershon AA, Steinberg S, Brunell PA. Zoster immune globulin. A further assessment. N Engl J Med 1974; 290:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/3/41016/abstract/23\">",
"      Orenstein WA, Heymann DL, Ellis RJ, et al. Prophylaxis of varicella in high-risk children: dose-response effect of zoster immune globulin. J Pediatr 1981; 98:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/3/41016/abstract/24\">",
"      Brunell PA, Gershon AA, Hughes WT, et al. Prevention of varicella in high risk children: a collaborative study. Pediatrics 1972; 50:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/3/41016/abstract/25\">",
"      ROSS AH. Modification of chicken pox in family contacts by administration of gamma globulin. N Engl J Med 1962; 267:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/3/41016/abstract/26\">",
"      Centers for Disease Control and Prevention (CDC). A new product (VariZIG) for postexposure prophylaxis of varicella available under an investigational new drug application expanded access protocol. MMWR Morb Mortal Wkly Rep 2006; 55:209.",
"     </a>",
"    </li>",
"    <li>",
"     VariZIG - Highlights of prescribing information. file://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/UCM333220.pdf (Accessed on December 22, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/3/41016/abstract/28\">",
"      Centers for Disease Control and Prevention (CDC). FDA approval of an extended period for administering VariZIG for postexposure prophylaxis of varicella. MMWR Morb Mortal Wkly Rep 2012; 61:212.",
"     </a>",
"    </li>",
"    <li>",
"     US Food and Drug Administration. FDA News Release. FDA approves Varizig for reducing chickenpox symptoms. file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm333233.htm (Accessed on December 24, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/3/41016/abstract/30\">",
"      Evans EB, Pollock TM, Cradock-Watson JE, Ridehalgh MK. Human anti-chickenpox immunoglobulin in the prevention of chickenpox. Lancet 1980; 1:354.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.cdc.gov/mmwr/preview/mmwrhtml/rr5604a1.htm (Accessed on July 08, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/3/41016/abstract/32\">",
"      Asano Y, Yoshikawa T, Suga S, et al. Postexposure prophylaxis of varicella in family contact by oral acyclovir. Pediatrics 1993; 92:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/3/41016/abstract/33\">",
"      Kaplan JE, Benson C, Holmes KH, et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009; 58:1.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8273 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-C7EAEF3114-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_3_41016=[""].join("\n");
var outline_f40_3_41016=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H878311\">",
"      GENERAL BACKGROUND",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H878525\">",
"      TRANSMISSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H878532\">",
"      Person to person",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H878571\">",
"      Mother to child",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H878751\">",
"      INCUBATION PERIOD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ASSESSMENT OF RISK OF INFECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H879120\">",
"      Determining susceptibility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H879579\">",
"      Types of exposure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H879742\">",
"      Role of serologic testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H929667\">",
"      TYPES OF POSTEXPOSURE PROPHYLAXIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H929999\">",
"      Who is eligible for varicella vaccine?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H929793\">",
"      Which patients require passive immunoprophylaxis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      EFFICACY OF IMMUNIZATION DURING OUTBREAKS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H880069\">",
"      VARICELLA VACCINE ADMINISTRATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H929977\">",
"      Available formulations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H879156\">",
"      Adverse events",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Testing for seroconversion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H930074\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PASSIVE IMMUNIZATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8196054\">",
"      General background",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H234145\">",
"      Historical perspective",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H234101\">",
"      - Zoster immune globulin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Varicella zoster immune globulin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      VariZIG",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H233733\">",
"      - Clinical data",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H151737850\">",
"      - Indications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8196144\">",
"      - Time interval from exposure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21573970\">",
"      - How to administer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8196327\">",
"      Intravenous immune globulin (IVIG)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Monitoring for infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      ACYCLOVIR FOR POSTEXPOSURE PROPHYLAXIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H878965\">",
"      Healthy children and adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Immunocompromised hosts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H879052\">",
"      Pregnant females",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H879861\">",
"      WHAT TO DO WHEN PROPHYLAXIS FAILS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/44/33480?source=related_link\">",
"      Clinical features of varicella-zoster virus infection: Chickenpox",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/57/25498?source=related_link\">",
"      Immunizations after hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/48/23306?source=related_link\">",
"      Immunizations in solid organ transplant candidates and recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/25/39318?source=related_link\">",
"      Patient information: Adult vaccines (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?2/40/2691?source=related_link\">",
"      Patient information: Chickenpox prevention and treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?36/18/37156?source=related_link\">",
"      Patient information: Vaccines for children age 7 to 18 years (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/28/32200?source=related_link\">",
"      Prevention and control of varicella in hospitals",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/26/37289?source=related_link\">",
"      Prevention of varicella-zoster virus infection: Chickenpox",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/36/23110?source=related_link\">",
"      Treatment of varicella-zoster virus infection: Chickenpox",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?8/8/8326?source=related_link\">",
"      Varicella-zoster immune globulin (human): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/11/4278?source=related_link\">",
"      Varicella-zoster infection in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/28/33225?source=related_link\">",
"      Varicella-zoster virus infection in pregnancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_3_41017="Postmastectomy chest wall irradiation";
var content_f40_3_41017=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Postmastectomy chest wall irradiation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/3/41017/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/3/41017/contributors\">",
"     Lori J Pierce, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/3/41017/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/3/41017/contributors\">",
"     Daniel F Hayes, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/3/41017/contributors\">",
"     David E Wazer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/3/41017/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/3/41017/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/3/41017/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The type of radiation therapy (RT) given after surgery for breast cancer varies with the primary surgical procedure:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Breast irradiation for women undergoing breast conserving therapy (BCT)",
"     </li>",
"     <li>",
"      Chest wall irradiation for women who have undergone mastectomy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Moderate dose RT, which is given after breast conserving therapy to eradicate any foci of residual microscopic disease, is associated with a large reduction in the rate of local recurrence and a beneficial impact on survival as well. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/7/11385?source=see_link\">",
"     \"Role of radiation therapy in breast conservation therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There do not appear to be any subsets of women who have a good enough prognosis following breast conserving surgery alone to warrant the elimination of whole breast RT. With the possible exception of older women with small hormone receptor-positive breast cancers who will be receiving adjuvant hormone therapy, whole breast RT is still the standard of care for",
"    <strong>",
"     all",
"    </strong>",
"    women undergoing breast conservation surgery for early stage breast cancer. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/7/11385?source=see_link\">",
"     \"Role of radiation therapy in breast conservation therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Postmastectomy chest wall RT has undergone a striking evolution. The popularity of this procedure was highest in the 1930s when women frequently presented with advanced stage breast cancer, with its attendant high risk of chest wall failure. Subsequently, it was routinely recommended to all women undergoing mastectomy who had positive axillary nodes; its use then declined precipitously following reports of an adverse impact on outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41017/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. More recently, a resurgence in use has followed reports of a survival benefit for postmastectomy chest wall RT and the identification of technique-related cardiac events as the reason for prior poor outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41017/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Postoperative chest wall RT can reduce a woman's risk of developing a chest wall failure, a potentially catastrophic event. At most, about 50 percent of such failures are ultimately controlled, and advancing chest wall disease can have a deleterious effect on a patient's quality of life.",
"   </p>",
"   <p>",
"    The indications and outcome from postmastectomy chest wall RT will be reviewed here. The technical aspects and complications are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/46/39657?source=see_link\">",
"     \"Techniques of breast and chest wall irradiation for early stage breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RATIONALE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Irradiation of the chest wall following mastectomy has two potential benefits: a decrease in the rate of locoregional recurrence and an increase in long-term survival.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Sites of locoregional recurrence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Assessment of locoregional patterns of failure identifies the chest wall and the",
"    <span class=\"nowrap\">",
"     supraclavicular/infraclavicular",
"    </span>",
"    regions as the most common sites of failure following mastectomy and adequate axillary dissection (ie, 10 or more nodes removed) (",
"    <a class=\"graphic graphic_figure graphicRef57770 \" href=\"mobipreview.htm?39/39/40563\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41017/abstract/4-8\">",
"     4-8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/52/42825?source=see_link&amp;anchor=H11#H11\">",
"     \"Management of the regional lymph nodes in breast cancer\", section on 'Axillary dissection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Over one-half of locoregional failures occur at the chest wall, with the mastectomy scar and the surrounding skin at greatest risk for recurrence [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/3/41017/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Up to 41 percent of locoregional recurrences occur in the",
"      <span class=\"nowrap\">",
"       supraclavicular/infraclavicular",
"      </span>",
"      region following a level",
"      <span class=\"nowrap\">",
"       I/II",
"      </span>",
"      axillary dissection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/3/41017/abstract/4-7\">",
"       4-7",
"      </a>",
"      ]. The rate of axillary failure in such patients is dependent upon the extent of axillary dissection. Following a level",
"      <span class=\"nowrap\">",
"       I/II",
"      </span>",
"      dissection, the 10-year risk of axillary failure is only 2 to 4 percent in contemporary series [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/3/41017/abstract/4,5\">",
"       4,5",
"      </a>",
"      ]. As a result, full axillary irradiation is usually not offered to such women. In contrast, less extensive axillary surgery is associated with a higher risk of axillary failure.",
"     </li>",
"     <li>",
"      The need to treat the internal mammary nodes is controversial. Although pathologic involvement has been reported in up to 37 percent of axillary node-positive breast cancers that are located in the inner or central breast [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/3/41017/abstract/10\">",
"       10",
"      </a>",
"      ], clinical evidence of recurrence at this site is uncommon [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/3/41017/abstract/4-7\">",
"       4-7",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Risk factors for locoregional recurrence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most consistent independent risk factors for locoregional recurrence are the number of positive nodes and the size of the primary tumor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Axillary nodes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Higher rates of locoregional failure are seen with greater numbers of involved axillary nodes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41017/abstract/4,5,9,11-18\">",
"     4,5,9,11-18",
"    </a>",
"    ]. In most series, locoregional failure rates following mastectomy without RT are 5 to 15 percent for women with one to three positive nodes and 15 to 50 percent in those with &ge;4 positive nodes at 10 years. The rate of recurrence is especially high in women with more than 10 positive nodes. In a report from the M. D. Anderson Cancer Center, for example, 10 year actuarial rates of isolated locoregional failure and locoregional failure as a component of relapse were 10 and 14 percent for one to three involved nodes; 21 and 25 percent for four to nine nodes; and 22 and 34 percent for &ge;10 nodes positive, respectively, following doxorubicin-based chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41017/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Postmastectomy chest wall RT is an effective means of reducing the rate of chest wall recurrence in women with multiple positive nodes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41017/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. The efficacy of this approach was illustrated in a retrospective analysis of 618 women with 10 or more positive axillary lymph nodes who were followed for an average of 7.5 years; 35 percent received adjuvant RT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41017/abstract/19\">",
"     19",
"    </a>",
"    ]. RT was associated with a significant reduction in locoregional recurrence (13 versus 38 percent), and significantly improved the five-year rates of distant failure (48 versus 58 percent, p = 0.02), and overall survival (56 versus 42 percent, p = 0.001).",
"   </p>",
"   <p>",
"    A related factor that appears to affect the cumulative rate of locoregional failure is the extent of axillary dissection, as measured by the number of nodes in the pathologic specimen. This was illustrated in an overview from the Eastern Cooperative Oncology Group (ECOG) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41017/abstract/4\">",
"     4",
"    </a>",
"    ]. Among women with one to three positive nodes, a significantly higher rate of axillary failure was observed when only two to five nodes were examined compared to 6 to 10 and &ge;11 nodes. Among women with &ge;4 nodes positive, a greater risk of supraclavicular failure was observed when only four to five nodes were examined compared to 6 to 10 and &ge;11 nodes. The ratio of the number of positive nodes to the number of excised nodes may be the best predictor of rates of recurrence and help to equate results from different series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41017/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Tumor size",
"    </span>",
"    &nbsp;&mdash;&nbsp;The size of the primary tumor is an independent risk factor for postmastectomy locoregional failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41017/abstract/4,11,22\">",
"     4,11,22",
"    </a>",
"    ]. In the ECOG report, for example, the 10-year risk of locoregional failure in women with T3 versus T1-2 lesions was significantly higher in those with both one to three positive nodes (31 versus 12 percent) and four to seven positive nodes (45 versus 20 percent) (",
"    <a class=\"graphic graphic_table graphicRef65393 \" href=\"mobipreview.htm?29/14/29920\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41017/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some data suggest that locoregional failure rates are low in women with node-negative, large primary tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41017/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. As an example, in a combined series of 8878 women enrolled in five NSABP trials who underwent mastectomy for node-negative tumors, the cumulative incidence rates of locoregional failure as a first event for tumors 5 cm or more than 5 cm, were 7 and 7.2 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41017/abstract/23\">",
"     23",
"    </a>",
"    ]. However, the median tumor size in this study was only 5.5 cm; locoregional failure rates in larger tumors were not addressed. Furthermore, a survival benefit from RT in patients with T3N0 disease has been shown in both of the Danish randomized trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41017/abstract/14,16\">",
"     14,16",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Danish trials'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The combined use of tumor size and nodal status may permit a better prediction of the likelihood of locoregional recurrence. In a recursive partitioning analysis of 1031 women treated with mastectomy without RT, tumor size &gt;3.5 cm, and metastatic involvement of more than 20 percent of the removed nodes, had a 41 percent chance of locoregional recurrence at eight years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41017/abstract/25\">",
"     25",
"    </a>",
"    ]. In contrast, women with less than 20 percent involved nodes and tumors &lt;5 cm were at lowest risk of locoregional recurrence (10 percent at eight years).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Extracapsular extension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although increased rates of locoregional failure occur in women with microscopic extracapsular extension (ECE) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41017/abstract/26-28\">",
"     26-28",
"    </a>",
"    ], these women also have a higher number of involved axillary nodes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41017/abstract/28-30\">",
"     28-30",
"    </a>",
"    ]. The rate of axillary failure is no higher in women with ECE, when the number of positive nodes is taken into account [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41017/abstract/27,31\">",
"     27,31",
"    </a>",
"    ]. Thus, the extent of nodal positivity rather than ECE appears to predict for increased rates of locoregional failure, and failure patterns show increased chest wall rather than axillary rates of recurrence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other factors that may help predict for locoregional recurrence include young age at diagnosis, hormone receptor status, the presence of lymphovascular invasion, and positive deep margin status [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41017/abstract/5,22,25,32\">",
"     5,22,25,32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Impact of systemic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Results from adjuvant therapy trials that have studied the effect of systemic therapy upon locoregional control have been contradictory. Some studies document a reduction in the risk of locoregional failure with chemotherapy and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41017/abstract/33-37\">",
"     33-37",
"    </a>",
"    ], while others show no effect upon local control [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41017/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. In the most recent meta-analysis of systemic therapy from the Early Breast Cancer Trialists' Collaborative Group (EBCTCG), five years of tamoxifen reduced the local recurrence rate by about one-half in women with hormone receptor-positive disease (local recurrence ratio 0.47), while, irrespective of hormone receptor status, polychemotherapy reduced it by about one-third (ratios 0.63 and 0.70 for women aged &lt;50 and 50 to 69, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41017/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nevertheless, in a later report from the EBCTCG, women who received adjuvant systemic therapy had a similar reduction in the incidence of locoregional failure from chest wall RT as those who did not receive adjuvant therapy (see below) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41017/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Impact of locoregional recurrence on survival",
"    </span>",
"    &nbsp;&mdash;&nbsp;Optimal locoregional control results in meaningful survival gains. Women who develop local recurrence have a higher rate of distant metastases, and most of these women will die of their cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41017/abstract/41\">",
"     41",
"    </a>",
"    ]. Some of the most important data linking better local control to enhanced survival come from the EBCTCG overview analyses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41017/abstract/40\">",
"     40",
"    </a>",
"    ]. Data from randomized trials of postmastectomy RT which demonstrate the importance of maximal locoregional control upon survival are also provided below. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Meta-analyses'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H14\">",
"     'Modern clinical trials'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    While it seems intuitive that women at high risk for locoregional failure may be those most likely to show a survival benefit, available data suggest that women at a lower risk for locoregional failure may derive the greatest survival benefit from postmastectomy RT. As an example, the British Columbia trial demonstrated significant benefits in overall survival with the use of postmastectomy RT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41017/abstract/15,42\">",
"     15,42",
"    </a>",
"    ]. There was a greater relative reduction in mortality in women with one to three positive nodes, compared to those with &ge;4 positive nodes (11 versus 7 percent absolute reduction in overall mortality, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41017/abstract/42\">",
"     42",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'British Columbia trial'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    This difference could reflect the greater survival benefit of adjuvant chemotherapy in women with fewer positive nodes, in whom eradication of micrometastatic disease might permit a survival benefit to become manifest as a result of improved locoregional control. However, this hypothesis has not been rigorously tested, and conclusions cannot be drawn from this study.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     POSTMASTECTOMY IRRADIATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Early clinical trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are few areas in clinical oncology that have received more extensive study than postmastectomy chest wall RT. Although interpretation of the results from early trials, in which accrual was accomplished between 1950 and 1980, is limited by the wide range of radiation techniques and dosing (",
"    <a class=\"graphic graphic_table graphicRef55536 \" href=\"mobipreview.htm?4/58/5037\">",
"     table 2",
"    </a>",
"    ), all trials reported a decrease in local chest wall recurrence with chest wall RT. Some found an increase in disease-free survival (DFS) and a reduction in the rate of distant metastases. However, none of these trials produced a significant increase in overall survival in the irradiated group compared to the controls.",
"   </p>",
"   <p>",
"    It is possible that increased use of adjuvant systemic chemotherapy has changed the number of women who have locoregional disease extension with no or few micrometastases, because chemotherapy has either eradicated all traces of micrometastatic disease or has reduced the tumor burden below a threshold necessary for clinical manifestation of metastases. Thus, early trials performed in women who did not receive adequate systemic chemotherapy may have less relevance for modern breast cancer management techniques that emphasize the importance of systemic treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Meta-analyses",
"    </span>",
"    &nbsp;&mdash;&nbsp;The technique of meta-analysis is a useful tool to assemble large groups of patients for retrospective analysis; several such analyses have examined the issue of postmastectomy chest wall RT. It is useful to review the sequence of analyses that have been performed.",
"   </p>",
"   <p>",
"    The first one, published in 1974, reviewed results from six early randomized studies of postmastectomy chest wall RT; a 1 to 10 percent reduction in survival was noted in the irradiated patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41017/abstract/1\">",
"     1",
"    </a>",
"    ]. The author postulated that RT might be causing immunosuppression and recommended that routine postmastectomy chest wall RT be discontinued [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41017/abstract/43,44\">",
"     43,44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This meta-analysis was updated by others in 1987, with a more thorough analysis that included updates of the trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41017/abstract/2\">",
"     2",
"    </a>",
"    ]. These authors concluded that 10-year survival was not improved in irradiated women compared to those undergoing mastectomy alone. However, after 10 years, the survival curves began to diverge, with irradiated patients doing worse. However, the majority of survivors followed beyond 10 years were from older trials in which orthovoltage RT was the predominant form of treatment, and the explanation for the excess in mortality was not clear since the cause of death was largely unknown.",
"   </p>",
"   <p>",
"    In a later update examining cause-specific mortality for these trials as well as several others, it became clear that an excess in late cardiac deaths was responsible for the detrimental effects of RT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41017/abstract/45\">",
"     45",
"    </a>",
"    ], as was previously reported in the individual trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41017/abstract/46-48\">",
"     46-48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The publication of this meta-analysis marked a turning point in the declining use of postmastectomy RT by demonstrating a benefit in breast cancer-specific survival following RT and providing an explanation for prior detrimental effects on survival. In more recent trials employing modern RT techniques, a reduction in breast cancer deaths followed the use of postmastectomy RT, and excess cardiac mortality was substantially reduced.",
"   </p>",
"   <p>",
"    The meta-analysis of Early Breast Cancer Trialists' Collaborative Group represents an expansion of the prior analysis presented above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41017/abstract/40\">",
"     40",
"    </a>",
"    ]. In the most recent update, 46 randomized trials involving over 23,000 patients were identified in which RT was used after simple mastectomy alone, simple mastectomy with axillary sampling, simple mastectomy with axillary clearance, or lumpectomy with axillary clearance. Some trials used systemic therapy while others did not. The conclusions of this meta-analysis are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      RT was associated with a significant reduction in breast cancer mortality. When the analysis was limited to trials of postmastectomy RT (which included 8505 women with node-positive and 1428 women with node-negative disease), the improvement in cause-specific survival was highly significant for women with node-positive (15-year breast cancer mortality for RT versus no RT 54.7 versus 60.1 percent, p = 0.0002). Among women with node-negative disease, breast cancer mortality was modestly but significantly higher among irradiated women (15-year mortality 31.3 versus 27.7 for RT and no RT, respectively, p = 0.01).",
"     </li>",
"     <li>",
"      RT was associated with a highly significant threefold reduction in the rate of local recurrence (annual odds ratio 0.31, five-year risk of local recurrence 7.3 versus 25.9 percent). For trials limited to postmastectomy RT in women undergoing mastectomy plus axillary clearance for node-positive breast cancer, the annual odds ratio was 0.28, five year risk of local recurrence 5.8 versus 22.8. The absolute reduction in local recurrence was similar among women with one to three positive nodes (4 versus 16 percent with and without RT, 12 percent absolute reduction) and those with four or more positive nodes (12 versus 26 percent, 14 percent absolute risk reduction).",
"     </li>",
"     <li>",
"      RT was associated with a significant excess incidence of contralateral breast cancer (annual odds ratio 1.18, p = 0.002) and a significant increase in the risk of death from causes other than breast cancer (annual odds ratio 1.12, p = 0.001). This excess mortality mainly involved heart disease and lung cancer. However, the averaged effects on mortality were not large (15-year non-breast cancer mortality 15.9 versus 14.6 percent for irradiated and nonirradiated women, respectively).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Yet another meta-analysis consisted of 18 randomized trials of 6367 women with node-positive breast cancer treated with systemic therapy, including the most recent randomized trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41017/abstract/49\">",
"     49",
"    </a>",
"    ]. A significant reduction in mortality was observed with postmastectomy RT (odds ratio [OR] 0.83, 95% CI 0.74-0.94). Although this analysis was strongly influenced by the positive results of the large premenopausal and postmenopausal Danish trials, it also included the results of 16 other trials published between 1967 and 1999. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Modern clinical trials'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Finally, others have emphasized the importance of the quality of the delivered RT (ie, dose, treatment field) to outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41017/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Modern clinical trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of postmastectomy RT has been evaluated in several trials that use modern radiotherapy techniques and systemic adjuvant chemotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Danish trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first Danish Breast Cancer Cooperative Group trial included 1708 premenopausal women with \"adverse features\" (92 percent had positive axillary lymph nodes, and the remainder, either T3 disease or invasion of the skin or pectoral fascia) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41017/abstract/14\">",
"     14",
"    </a>",
"    ]. All patients underwent mastectomy, axillary sampling and postoperative adjuvant chemotherapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , and 5-fluorouracil (CMF) chemotherapy and were then randomly assigned to receive chest wall and regional nodal irradiation (supraclavicular, axilla, and internal mammary nodes) between cycles 1 and 2 of CMF, or no adjuvant RT. With a median follow-up of just under 10 years, postmastectomy radiotherapy was associated with a significant reduction in locoregional failure (32 versus 9 percent), and significantly improved disease-free survival (DFS) (48 versus 34 percent) as well as overall survival (54 versus 45 percent).",
"   </p>",
"   <p>",
"    One criticism of the Danish trial is that few axillary lymph nodes were removed (median of seven), making it likely that many women had disease left behind in the axilla following axillary sampling. The importance of this was illustrated by the observations that 44 percent of the locoregional recurrences in the CMF alone arm were in axillary lymph nodes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41017/abstract/51\">",
"     51",
"    </a>",
"    ], in stark contrast to the rarity of axillary failure following a level I or II axillary dissection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41017/abstract/52\">",
"     52",
"    </a>",
"    ]. The treatment of such residual axillary disease with CMF plus radiotherapy in one arm and only CMF in the other could have contributed to both the DFS and overall survival difference. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/52/42825?source=see_link\">",
"     \"Management of the regional lymph nodes in breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The benefit of postmastectomy RT for postmenopausal women at high risk for locoregional recurrence was explored in a second Danish trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41017/abstract/16\">",
"     16",
"    </a>",
"    ]. Between 1982 and 1990, 1375 postmenopausal women with stage II or III breast cancer were randomly assigned to adjuvant",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    (30",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for one year) alone or with postoperative chest wall and regional nodal irradiation. The use of RT was associated with significantly fewer locoregional recurrences (8 versus 35 percent), a significant improvement in 10-year DFS (36 versus 24 percent), and overall survival (45 versus 36 percent, p = 0.03). Of note, 58 percent of the women in this trial had between one and three positive nodes, and a similar degree of benefit was noted for women with either 1 to 3 or &ge;4 positive nodes.",
"   </p>",
"   <p>",
"    In a later update of combined data from both the premenopausal and postmenopausal trials (total 3083 patients), the RT group had a significantly lower 18-year probability of any first breast cancer event (59 versus 73 percent) and locoregional failure (14 versus 49 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41017/abstract/53\">",
"     53",
"    </a>",
"    ]. In addition, RT was also associated with significantly lower rates of distant metastases subsequent to locoregional relapse (35 versus 6 percent), as well as distant metastases overall (64 versus 53 percent, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41017/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     British Columbia trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the British Columbia trial, 318 premenopausal women with node-positive breast cancer undergoing mastectomy and axillary dissection were randomly assigned to CMF plus chest wall radiotherapy (chest wall and regional lymph nodes, including the internal mammary nodes) versus CMF alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41017/abstract/15\">",
"     15",
"    </a>",
"    ]. As in the Danish trial, postmastectomy RT was associated with significant reduction in locoregional failure, and DFS at 15 years was also significantly improved (50 versus 33 percent). In the initial publication, a trend toward improved overall survival was seen (54 versus 46 percent). The beneficial effects of radiotherapy were noted in women with one to three positive lymph nodes, as well as those with &ge;4 nodes.",
"   </p>",
"   <p>",
"    In contrast to the Danish studies cited above, in which the small number of lymph nodes removed made determination of lymph node subgroups nearly impossible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41017/abstract/14\">",
"     14",
"    </a>",
"    ], the median number of axillary nodes removed was 11. Nevertheless, the rates of locoregional recurrence were higher than expected in the control group (rates of locoregional recurrence-free survival at 5, 10, and 15 years in the chemotherapy alone group were 79, 75, and 67 percent, respectively; the corresponding rates in the RT group were 90, 87, and 87 percent, respectively).",
"   </p>",
"   <p>",
"    A later report with 20-year follow-up demonstrated a significant survival benefit in favor of postmastectomy RT (overall survival 47 versus 37 percent, HR 0.73 95% CI 0.55 to 0.98) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41017/abstract/42\">",
"     42",
"    </a>",
"    ]. The relative magnitude of benefit from RT appeared to be similar in women with one to three positive nodes (HR 0.76, 95% CI 0.50 to 1.15) corresponding to a 7 percent absolute improvement in overall survival (57 versus 50 percent), as in those with &ge;4 positive nodes (HR 0.70, 95% CI 0.46-1.06), corresponding to a 14 percent absolute improvement in overall survival (31 versus 17 percent).",
"   </p>",
"   <p>",
"    Some aspects of the RT technique used in this study bear mention. The rapid fractionation scheme (2.5 Gy per fraction to a total of 37.5 Gy) is more common in Canada than in the United States. In addition, the internal mammary nodes were treated with a direct en face field. Such a field has been implicated in late long-term cardiac morbidity and mortality. Although no excess mortality could be attributed to the long-term side effects of radiotherapy, longer term follow-up will be necessary. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/21/34137?source=see_link\">",
"     \"Cardiotoxicity of radiation therapy for malignancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Limitations",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are some caveats to the interpretation of these three randomized trials that should be considered when incorporating this information into practice guidelines, particularly for women with one to three involved axillary nodes.",
"   </p>",
"   <p>",
"    The extent of axillary dissection influences the risk and pattern of locoregional failures. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Axillary nodes'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    As previously noted, in American series, 10-year locoregional failure rates following mastectomy without RT are 5 to 15 percent for women who are found to have one to three positive nodes after a full axillary node dissection. The local failure rates in the British Columbia and Danish trials in the control groups exceed these estimates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41017/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. As an example, in the premenopausal Danish trial, the rates of locoregional recurrence in the control and treated groups were 30 and 13 percent, leading some to question the extent of axillary dissection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41017/abstract/14\">",
"     14",
"    </a>",
"    ]. In fact, the median number of dissected axillary nodes was only seven in the Danish trials and 11 in the British Columbia trial.",
"   </p>",
"   <p>",
"    A later meta-analysis of data from the Danish trials included a subset of 1512 node-positive patients who had at least eight nodes removed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41017/abstract/54\">",
"     54",
"    </a>",
"    ]. Although the survival benefit seen with RT was similar in the groups with one to three positive, and four or more positive nodes, those with four or more nodes had a far greater improvement in local control with RT than did those with fewer positive nodes.",
"   </p>",
"   <p>",
"    Some have argued that with a more complete axillary dissection, most of the patients with one to three positive nodes would actually have been found to have four or more positive nodes, thus accounting for the apparent survival benefit in this subgroup. This issue has been studied by several investigators [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41017/abstract/55-58\">",
"     55-58",
"    </a>",
"    ]. Taken together, the available data suggest that approximately 50 to 71 percent of patients who are found to have one to three positive nodes after a limited dissection will not be found to have additional positive nodes after a more complete dissection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Positive lymph nodes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The results of the Danish and Canadian trials suggest that",
"    <strong>",
"     all",
"    </strong>",
"    patients with node-positive operable breast cancer may benefit from RT following mastectomy in terms of both breast-cancer-specific and overall survival. Both the British Columbia trial, and the meta-analysis of all three trials demonstrated a similar proportional impact of treatment on survival for women with small numbers of positive lymph nodes, underscoring the benefit of RT for all node-positive subsets [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41017/abstract/42,54\">",
"     42,54",
"    </a>",
"    ]. However, the surgical limitations of these studies, particularly the Danish trials, have led to a reluctance to generalize these recommendations to American practice, particularly for patients with one to three positive nodes, whose prognosis is relatively favorable. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Limitations'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Locoregional relapse risk increases approximately linearly with the number of positive lymph nodes. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Axillary nodes'",
"    </a>",
"    above.) Based upon consistent rates of locoregional recurrence of 15 to 20 percent or more, most experts agree that postmastectomy RT should be delivered to all premenopausal and postmenopausal women with &ge;4 positive nodes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41017/abstract/59-63\">",
"     59-63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9984215\">",
"    <span class=\"h3\">",
"     Fewer positive nodes",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is far less agreement on patients with fewer positive nodes, whose risk of locoregional relapse is lower. However, the subsetting of patients into groups with one to three, or four or more positive nodes is an artificial distinction that originated in the early days of adjuvant systemic chemotherapy, when it was suggested that adjuvant chemotherapy benefited only those with four or more positive nodes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41017/abstract/64\">",
"     64",
"    </a>",
"    ], a finding that has since been discredited. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/4/37961?source=see_link\">",
"     \"Adjuvant chemotherapy for hormone receptor-positive or negative, HER2-negative breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Given that node-positive breast cancer represents a continuum, it is difficult to conceive that a patient with three positive nodes would not be at high enough risk to justify treatment, whereas a patient with four positive nodes would qualify as high-risk. As noted above, data from a combined analysis of the two Danish trials suggests that the survival benefit from postmastectomy RT is similar in patients with one to three, or four or more positive nodes, although the recurrence rates in these trials are much higher than would be expected after a standard ALND [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41017/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additional data to support benefit from RT in patients with fewer than four positive nodes comes from the NCIC CTG MA.20 trial, which demonstrated a significant locoregional and distant disease-free survival benefit (as well as a trend toward better overall survival) for the addition of locoregional irradiation to whole breast RT in women undergoing breast conserving therapy; 85 percent of enrolled patients had one to three positive lymph nodes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/7/11385?source=see_link&amp;anchor=H730200#H730200\">",
"     \"Role of radiation therapy in breast conservation therapy\", section on 'Benefits of regional nodal irradiation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These issues have led many to conclude that postmastectomy RT is an appropriate option for the majority of patients with node-positive breast cancer, regardless of the number of involved nodes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41017/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, there may be subsets of women with node-negative breast cancer who might derive benefit from the addition of postmastectomy RT. One example is women with &ldquo;triple-negative&rdquo; breast cancer (TNBC), which is defined by absent expression of the three most commonly evaluated biomarkers (the estrogen receptor [ER], progesterone receptor [PR], and the human epidermal growth factor receptor 2 [HER2] protein). TNBC is characterized by an aggressive clinical course, a unique pattern of early relapse, a higher incidence of visceral and brain as compared to bone and soft tissue metastases, and a relatively poor prognosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/40/34441?source=see_link\">",
"     \"Epidemiology, risk factors and the clinical approach to ER/PR negative, HER2-negative (Triple-negative) breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Women with TNBC treated with mastectomy alone appear to be at a higher than expected risk of locoregional recurrence, even if node-negative [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41017/abstract/66\">",
"     66",
"    </a>",
"    ]. The benefits of postmastectomy RT were directly addressed in a randomized trial in which 681 women with TNBC undergoing mastectomy (82 percent node-negative) were randomly assigned to adjuvant chemotherapy with or without postmastectomy chest wall irradiation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41017/abstract/67\">",
"     67",
"    </a>",
"    ]. At a median follow-up of 86 months, patients who received postmastectomy chest wall irradiation had significantly better five-year relapse-free survival (88 versus 75 percent) and overall survival (90 versus 79 percent) as compared to those who received chemotherapy alone.",
"   </p>",
"   <p>",
"    These data require independent confirmation before postmastectomy radiotherapy becomes standard of care in node-negative women with triple-negative breast cancer; however, until additional data are available, women with TNBC who are undergoing mastectomy should be referred for consultation to discuss the pros and cons of postmastectomy chest wall irradiation, even if node-negative.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Positive deep margins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with clinical T1-2 tumor size, and zero to three positive axillary lymph nodes with a positive deep margin appear to be at increased risk for locoregional recurrence and should be offered postmastectomy irradiation. In one series, premenopausal women with a close or positive margin had a 28 percent risk of chest wall recurrence, regardless of the use of adjuvant systemic therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41017/abstract/68\">",
"     68",
"    </a>",
"    ]. In another report of 94 patients with a positive surgical margin after mastectomy, the locoregional failure rates with and without postmastectomy RT were 4.8 and 15.1 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41017/abstract/69\">",
"     69",
"    </a>",
"    ]. The risks were higher if additional prognostic factors were also present (eg, T2 tumor size, lymphovascular invasion, grade 3 disease).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Locally advanced breast cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with locally advanced node-negative breast cancer who are treated with chemotherapy followed by mastectomy should also receive postmastectomy chest wall irradiation. While the survival impact for chest wall irradiation in this setting is unclear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41017/abstract/70,71\">",
"     70,71",
"    </a>",
"    ], the improvement in locoregional control in these women who are at high risk for chest wall failure makes RT an important part of their management. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/46/19177?source=see_link&amp;anchor=H528513711#H528513711\">",
"     \"Overview of the treatment of newly diagnosed, non-metastatic breast cancer\", section on 'Locally advanced breast cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9984477\">",
"    <span class=\"h3\">",
"     Guidelines from expert groups",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guidelines from major groups do not endorse RT in the subset of patients with one to three positive nodes. However, most were written before the analyses from the Danish and British Columbia trials, which specifically looked at the subset with one to three positive nodes. The most recent National Comprehensive Cancer Network (NCCN) guidelines suggest that postmastectomy RT to the chest wall and supraclavicular area be strongly considered after chemotherapy in women with one to three positive nodes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41017/abstract/62\">",
"     62",
"    </a>",
"    ]. However, there was no consensus on the issue of whether the internal mammary nodes should be included in the RT field.",
"   </p>",
"   <p>",
"    2001 ASCO clinical practice guidelines recommend the use of postmastectomy RT in the following situations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41017/abstract/60\">",
"     60",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with four or more positive axillary lymph nodes",
"     </li>",
"     <li>",
"      T3 and T4 tumors (",
"      <a class=\"graphic graphic_table graphicRef65393 \" href=\"mobipreview.htm?29/14/29920\">",
"       table 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      There was insufficient evidence for the panel to recommend routine chest wall radiotherapy for women with one to three positive axillary nodes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar guidelines have been published from Canada [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41017/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Guidelines from the American Society for Radiation Oncology (ASTRO), published in 1999, recommend postmastectomy chest wall irradiation in the setting of four or more positive nodes, but do not address other indications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41017/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These guidelines notwithstanding, in our view and that of others [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41017/abstract/65\">",
"     65",
"    </a>",
"    ], all patients with one to three positive nodes should be referred to a radiation oncologist for a thoughtful discussion of the benefits and risks of treatment so that they may make an informed decision.",
"   </p>",
"   <p>",
"    Further information should be forthcoming from a European trial that is currently accruing patients (the SUPREMO trial, for Selective Use of Postoperative Radiotherapy after Mastectomy), which is being run by the Scottish Cancer Trials Breast Group. It randomly assigns high-risk women (including those with node-negative large tumors and one to three positive nodes) to postmastectomy RT or no RT.",
"   </p>",
"   <p>",
"    Researchers have also examined biologic factors as predictors of those patients who derive the greatest benefit from postmastectomy radiotherapy. In one study, PMRT significantly reduced locoregional recurrence in all patients but those that were",
"    <span class=\"nowrap\">",
"     ER/PR",
"    </span>",
"    negative and HER2-positive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41017/abstract/72\">",
"     72",
"    </a>",
"    ]. Overall survival following PMRT was only improved in those patients with",
"    <span class=\"nowrap\">",
"     ER/PR",
"    </span>",
"    positive, HER2-negative cancers and",
"    <span class=\"nowrap\">",
"     ER/PR",
"    </span>",
"    positive, HER2-positive cancers. While these results are hypothesis-generating at this time, if verified by others, they suggest further tailoring of recommendations for treatment based upon biologic characteristics of the tumor and the need to modify treatment in patients with",
"    <span class=\"nowrap\">",
"     ER/PR/HER2-negative",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     ER/PR",
"    </span>",
"    negative HER2-positive disease. In the future, techniques such as gene expression profiling might prove useful for predicting which of these patients are at risk for locoregional recurrence, and thus stand to benefit from postmastectomy RT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41017/abstract/73\">",
"     73",
"    </a>",
"    ]. At least some data suggest that higher nodal ratios (ie, a ratio of positive nodes to total number of excised nodes &ge;0.2) might permit the identification of patients with one to three positive nodes who have the highest risk of a locoregional recurrence, and therefore, stand to benefit the most from the addition of postmastectomy RT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41017/abstract/21\">",
"     21",
"    </a>",
"    ]. However, this approach requires confirmation and validation in prospective trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Timing of treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;RT techniques for treatment of the chest wall are discussed elsewhere. Almost all women with positive axillary lymph nodes will receive adjuvant systemic therapy, with combination chemotherapy,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    , or both. The concomitant administration of cytotoxic chemotherapy and RT is generally avoided, particularly when doxorubicin-based therapy is administered, because of concerns for enhanced toxicity. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/46/39657?source=see_link\">",
"     \"Techniques of breast and chest wall irradiation for early stage breast cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/21/34137?source=see_link\">",
"     \"Cardiotoxicity of radiation therapy for malignancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As with RT as a component of breast conserving therapy, a delay in the institution of postmastectomy RT of up to six months to permit the administration of adjuvant systemic chemotherapy does not appear to compromise locoregional control [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41017/abstract/74\">",
"     74",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/4/37961?source=see_link\">",
"     \"Adjuvant chemotherapy for hormone receptor-positive or negative, HER2-negative breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The influence of the specific sequence of therapy was directly addressed in one trial in which 244 women with stage I or II breast cancer were randomly assigned to 12 weeks of chemotherapy either before or after adjuvant RT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41017/abstract/75,76\">",
"     75,76",
"    </a>",
"    ]. In the latest update with over 10 years of follow-up, there were no significant differences between the two groups in locoregional or distant failure rate, time to failure, time to distant metastasis, or time to death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/3/41017/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sequencing chest wall RT with systemic chemotherapy can be done in various ways. Four to six months of chemotherapy as the patient's initial postmastectomy treatment is often delivered followed by chest wall irradiation. If non-doxorubicin-based chemotherapy is given, it is possible to deliver the two therapies simultaneously, although",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    is generally omitted from simultaneous therapy due to concerns of increase acute skin toxicity and increased pneumonitis risk. Radiotherapy can also be delivered between successive cycles of chemotherapy (\"sandwich approach\" as per the Danish and British Columbia trials). (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Modern clinical trials'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The timing of breast reconstruction in women who are receiving postmastectomy RT is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/29/39386?source=see_link&amp;anchor=H2464163#H2464163\">",
"     \"Breast reconstruction in women with breast cancer\", section on 'Radiation therapy and reconstruction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The addition of postmastectomy irradiation in high risk women reduces the risk of locoregional recurrence, increases disease-free survival, and reduces a woman's risk of dying from breast cancer. Both premenopausal and postmenopausal women appear to benefit. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We agree with guidelines published from multiple organizations and recommend postmastectomy chest wall irradiation for all women with &ge;4 positive nodes (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Positive lymph nodes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with one to three pathologically involved nodes or T3 tumors (without nodal involvement), a decision about RT should be individualized based on a discussion between the patient and a radiation oncologist about the pros and cons of chest wall irradiation. (See",
"      <a class=\"local\" href=\"#H9984215\">",
"       'Fewer positive nodes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Women with triple negative breast cancer (ie, those whose tumors lack expression of hormone receptors and HER2) may be at higher risk for locoregional recurrence. In our view, these women should be referred for consultation to discuss the pros and cons of irradiation regardless of nodal status. (See",
"      <a class=\"local\" href=\"#H9984215\">",
"       'Fewer positive nodes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend postmastectomy chest wall irradiation for women with positive deep margins (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Positive deep margins'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with T3 tumors, we suggest RT, regardless of the status of the nodes (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Locally advanced breast cancer'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/3/41017/abstract/1\">",
"      Stjernsw&auml;rd J. Decreased survival related to irradiation postoperatively in early operable breast cancer. Lancet 1974; 2:1285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/3/41017/abstract/2\">",
"      Cuzick J, Stewart H, Peto R, et al. Overview of randomized trials of postoperative adjuvant radiotherapy in breast cancer. Cancer Treat Rep 1987; 71:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/3/41017/abstract/3\">",
"      White J, Moughan J, Pierce LJ, et al. Status of postmastectomy radiotherapy in the United States: a patterns of care study. Int J Radiat Oncol Biol Phys 2004; 60:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/3/41017/abstract/4\">",
"      Recht A, Gray R, Davidson NE, et al. Locoregional failure 10 years after mastectomy and adjuvant chemotherapy with or without tamoxifen without irradiation: experience of the Eastern Cooperative Oncology Group. J Clin Oncol 1999; 17:1689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/3/41017/abstract/5\">",
"      Katz A, Strom EA, Buchholz TA, et al. Locoregional recurrence patterns after mastectomy and doxorubicin-based chemotherapy: implications for postoperative irradiation. J Clin Oncol 2000; 18:2817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/3/41017/abstract/6\">",
"      Strom EA, Woodward WA, Katz A, et al. Clinical investigation: regional nodal failure patterns in breast cancer patients treated with mastectomy without radiotherapy. Int J Radiat Oncol Biol Phys 2005; 63:1508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/3/41017/abstract/7\">",
"      Schwaibold F, Fowble BL, Solin LJ, et al. The results of radiation therapy for isolated local regional recurrence after mastectomy. Int J Radiat Oncol Biol Phys 1991; 21:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/3/41017/abstract/8\">",
"      Toonkel LM, Fix I, Jacobson LH, Wallach CB. The significance of local recurrence of carcinoma of the breast. Int J Radiat Oncol Biol Phys 1983; 9:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/3/41017/abstract/9\">",
"      Donegan WL, Perez-Mesa CM, Watson FR. A biostatistical study of locally recurrent breast carcinoma. Surg Gynecol Obstet 1966; 122:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/3/41017/abstract/10\">",
"      Lacour J, Le M, Caceres E, et al. Radical mastectomy versus radical mastectomy plus internal mammary dissection. Ten year results of an international cooperative trial in breast cancer. Cancer 1983; 51:1941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/3/41017/abstract/11\">",
"      Taghian A, Jeong JH, Mamounas E, et al. Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy: results from five National Surgical Adjuvant Breast and Bowel Project randomized clinical trials. J Clin Oncol 2004; 22:4247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/3/41017/abstract/12\">",
"      Stefanik D, Goldberg R, Byrne P, et al. Local-regional failure in patients treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 1985; 3:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/3/41017/abstract/13\">",
"      Griem KL, Henderson IC, Gelman R, et al. The 5-year results of a randomized trial of adjuvant radiation therapy after chemotherapy in breast cancer patients treated with mastectomy. J Clin Oncol 1987; 5:1546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/3/41017/abstract/14\">",
"      Overgaard M, Hansen PS, Overgaard J, et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med 1997; 337:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/3/41017/abstract/15\">",
"      Ragaz J, Jackson SM, Le N, et al. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Engl J Med 1997; 337:956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/3/41017/abstract/16\">",
"      Overgaard M, Jensen MB, Overgaard J, et al. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet 1999; 353:1641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/3/41017/abstract/17\">",
"      Mentzer SJ, Osteen RT, Wilson RE. Local recurrence and the deep resection margin in carcinoma of the breast. Surg Gynecol Obstet 1986; 163:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/3/41017/abstract/18\">",
"      Fowble B, Gray R, Gilchrist K, et al. Identification of a subgroup of patients with breast cancer and histologically positive axillary nodes receiving adjuvant chemotherapy who may benefit from postoperative radiotherapy. J Clin Oncol 1988; 6:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/3/41017/abstract/19\">",
"      Diab SG, Hilsenbeck SG, de Moor C, et al. Radiation therapy and survival in breast cancer patients with 10 or more positive axillary lymph nodes treated with mastectomy. J Clin Oncol 1998; 16:1655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/3/41017/abstract/20\">",
"      Smith BD, Smith GL, Haffty BG. Postmastectomy radiation and mortality in women with T1-2 node-positive breast cancer. J Clin Oncol 2005; 23:1409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/3/41017/abstract/21\">",
"      Truong PT, Woodward WA, Thames HD, et al. The ratio of positive to excised nodes identifies high-risk subsets and reduces inter-institutional differences in locoregional recurrence risk estimates in breast cancer patients with 1-3 positive nodes: an analysis of prospective data from British Columbia and the M. D. Anderson Cancer Center. Int J Radiat Oncol Biol Phys 2007; 68:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/3/41017/abstract/22\">",
"      Jagsi R, Raad RA, Goldberg S, et al. Locoregional recurrence rates and prognostic factors for failure in node-negative patients treated with mastectomy: implications for postmastectomy radiation. Int J Radiat Oncol Biol Phys 2005; 62:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/3/41017/abstract/23\">",
"      Taghian AG, Jeong JH, Mamounas EP, et al. Low locoregional recurrence rate among node-negative breast cancer patients with tumors 5 cm or larger treated by mastectomy, with or without adjuvant systemic therapy and without radiotherapy: results from five national surgical adjuvant breast and bowel project randomized clinical trials. J Clin Oncol 2006; 24:3927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/3/41017/abstract/24\">",
"      Floyd SR, Buchholz TA, Haffty BG, et al. Low local recurrence rate without postmastectomy radiation in node-negative breast cancer patients with tumors 5 cm and larger. Int J Radiat Oncol Biol Phys 2006; 66:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/3/41017/abstract/25\">",
"      Katz A, Buchholz TA, Thames H, et al. Recursive partitioning analysis of locoregional recurrence patterns following mastectomy: implications for adjuvant irradiation. Int J Radiat Oncol Biol Phys 2001; 50:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/3/41017/abstract/26\">",
"      Kuske RR, Sanchez M, Farr GH, et al. Extracapsular axillary nodal extension (ECE) in breast cancer: patterns of recurrence, arm edema, and survival after mastectomy with and without irradiation (abstract). Int J Radiat Oncol Biol Phys 1999; 45:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/3/41017/abstract/27\">",
"      Mignano JE, Zahurak ML, Chakravarthy A, et al. Significance of axillary lymph node extranodal soft tissue extension and indications for postmastectomy irradiation. Cancer 1999; 86:1258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/3/41017/abstract/28\">",
"      Donegan WL, Stine SB, Samter TG. Implications of extracapsular nodal metastases for treatment and prognosis of breast cancer. Cancer 1993; 72:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/3/41017/abstract/29\">",
"      Leonard C, Corkill M, Tompkin J, et al. Are axillary recurrence and overall survival affected by axillary extranodal tumor extension in breast cancer? Implications for radiation therapy. J Clin Oncol 1995; 13:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/3/41017/abstract/30\">",
"      Hetelekidis S, Schnitt SJ, Silver B, et al. The significance of extracapsular extension of axillary lymph node metastases in early-stage breast cancer. Int J Radiat Oncol Biol Phys 2000; 46:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/3/41017/abstract/31\">",
"      Gruber G, Bonetti M, Nasi ML, et al. Prognostic value of extracapsular tumor spread for locoregional control in premenopausal patients with node-positive breast cancer treated with classical cyclophosphamide, methotrexate, and fluorouracil: long-term observations from International Breast Cancer Study Group Trial VI. J Clin Oncol 2005; 23:7089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/3/41017/abstract/32\">",
"      Cheng SH, Horng CF, Clarke JL, et al. Prognostic index score and clinical prediction model of local regional recurrence after mastectomy in breast cancer patients. Int J Radiat Oncol Biol Phys 2006; 64:1401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/3/41017/abstract/33\">",
"      Fisher B, Fisher ER, Redmond C. Ten-year results from the National Surgical Adjuvant Breast and Bowel Project (NSABP) clinical trial evaluating the use of L-phenylalanine mustard (L-PAM) in the management of primary breast cancer. J Clin Oncol 1986; 4:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/3/41017/abstract/34\">",
"      Richards MA, O'Reilly SM, Howell A, et al. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in patients with axillary node-positive breast cancer: an update of the Guy's/Manchester trial. J Clin Oncol 1990; 8:2032.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/3/41017/abstract/35\">",
"      Castiglione M, Gelber RD, Goldhirsch A. Adjuvant systemic therapy for breast cancer in the elderly: competing causes of mortality. International Breast Cancer Study Group. J Clin Oncol 1990; 8:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/3/41017/abstract/36\">",
"      Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365:1687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/3/41017/abstract/37\">",
"      Falkson HC, Gray R, Wolberg WH, et al. Adjuvant trial of 12 cycles of CMFPT followed by observation or continuous tamoxifen versus four cycles of CMFPT in postmenopausal women with breast cancer: an Eastern Cooperative Oncology Group phase III study. J Clin Oncol 1990; 8:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/3/41017/abstract/38\">",
"      Morrison JM, Howell A, Kelly KA, et al. West Midlands Oncology Association trials of adjuvant chemotherapy in operable breast cancer: results after a median follow-up of 7 years. I. Patients with involved axillary lymph nodes. Br J Cancer 1989; 60:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/3/41017/abstract/39\">",
"      Misset JL, di Palma M, Delgado M, et al. Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: final report after a 16-year median follow-up duration. J Clin Oncol 1996; 14:1136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/3/41017/abstract/40\">",
"      Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 366:2087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/3/41017/abstract/41\">",
"      Arriagada R, Rutqvist LE, Mattsson A, et al. Adequate locoregional treatment for early breast cancer may prevent secondary dissemination. J Clin Oncol 1995; 13:2869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/3/41017/abstract/42\">",
"      Ragaz J, Olivotto IA, Spinelli JJ, et al. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. J Natl Cancer Inst 2005; 97:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/3/41017/abstract/43\">",
"      Stjernsward J. Proceedings: Does radiation induced immunosuppression influence distant metastases in mammary carcinoma? Br J Radiol 1975; 48:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/3/41017/abstract/44\">",
"      Stjernsward J. Can survival be decreased by post-operative irradiation. Int J Radiat Oncol Biol Phys 1977; 2:1171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/3/41017/abstract/45\">",
"      Cuzick J, Stewart H, Rutqvist L, et al. Cause-specific mortality in long-term survivors of breast cancer who participated in trials of radiotherapy. J Clin Oncol 1994; 12:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/3/41017/abstract/46\">",
"      Haybittle JL, Brinkley D, Houghton J, et al. Postoperative radiotherapy and late mortality: evidence from the Cancer Research Campaign trial for early breast cancer. BMJ 1989; 298:1611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/3/41017/abstract/47\">",
"      Rutqvist LE, Lax I, Fornander T, Johansson H. Cardiovascular mortality in a randomized trial of adjuvant radiation therapy versus surgery alone in primary breast cancer. Int J Radiat Oncol Biol Phys 1992; 22:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/3/41017/abstract/48\">",
"      H&oslash;st H, Brennhovd IO, Loeb M. Postoperative radiotherapy in breast cancer--long-term results from the Oslo study. Int J Radiat Oncol Biol Phys 1986; 12:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/3/41017/abstract/49\">",
"      Whelan TJ, Julian J, Wright J, et al. Does locoregional radiation therapy improve survival in breast cancer? A meta-analysis. J Clin Oncol 2000; 18:1220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/3/41017/abstract/50\">",
"      Gebski V, Lagleva M, Keech A, et al. Survival effects of postmastectomy adjuvant radiation therapy using biologically equivalent doses: a clinical perspective. J Natl Cancer Inst 2006; 98:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/3/41017/abstract/51\">",
"      Overgaard M, Christensen JJ, Johansen H, et al. Postmastectomy irradiation in high-risk breast cancer patients. Present status of the Danish Breast Cancer Cooperative Group trials. Acta Oncol 1988; 27:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/3/41017/abstract/52\">",
"      Recht A, Houlihan MJ. Axillary lymph nodes and breast cancer: a review. Cancer 1995; 76:1491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/3/41017/abstract/53\">",
"      Danish Breast Cancer Cooperative Group, Nielsen HM, Overgaard M, et al. Study of failure pattern among high-risk breast cancer patients with or without postmastectomy radiotherapy in addition to adjuvant systemic therapy: long-term results from the Danish Breast Cancer Cooperative Group DBCG 82 b and c randomized studies. J Clin Oncol 2006; 24:2268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/3/41017/abstract/54\">",
"      Overgaard M, Nielsen HM, Overgaard J. Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&amp;c randomized trials. Radiother Oncol 2007; 82:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/3/41017/abstract/55\">",
"      Danforth DN Jr, Findlay PA, McDonald HD, et al. Complete axillary lymph node dissection for stage I-II carcinoma of the breast. J Clin Oncol 1986; 4:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/3/41017/abstract/56\">",
"      Saha S, Farrar WB, Young DC, et al. Variation in axillary node dissection influences the degree of nodal involvement in breast cancer patients. J Surg Oncol 2000; 73:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/3/41017/abstract/57\">",
"      Iyer RV, Hanlon A, Fowble B, et al. Accuracy of the extent of axillary nodal positivity related to primary tumor size, number of involved nodes, and number of nodes examined. Int J Radiat Oncol Biol Phys 2000; 47:1177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/3/41017/abstract/58\">",
"      Kiricuta CI, Tausch J. A mathematical model of axillary lymph node involvement based on 1446 complete axillary dissections in patients with breast carcinoma. Cancer 1992; 69:2496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/3/41017/abstract/59\">",
"      Harris JR, Halpin-Murphy P, McNeese M, et al. Consensus Statement on postmastectomy radiation therapy. Int J Radiat Oncol Biol Phys 1999; 44:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/3/41017/abstract/60\">",
"      Recht A, Edge SB, Solin LJ, et al. Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001; 19:1539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/3/41017/abstract/61\">",
"      Eifel P, Axelson JA, Costa J, et al. National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst 2001; 93:979.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/3/41017/abstract/63\">",
"      Truong PT, Olivotto IA, Whelan TJ, et al. Clinical practice guidelines for the care and treatment of breast cancer: 16. Locoregional post-mastectomy radiotherapy. CMAJ 2004; 170:1263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/3/41017/abstract/64\">",
"      Fisher B, Ravdin RG, Ausman RK, et al. Surgical adjuvant chemotherapy in cancer of the breast: results of a decade of cooperative investigation. Ann Surg 1968; 168:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/3/41017/abstract/65\">",
"      Marks LB, Zeng J, Prosnitz LR. One to three versus four or more positive nodes and postmastectomy radiotherapy: time to end the debate. J Clin Oncol 2008; 26:2075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/3/41017/abstract/66\">",
"      Abdulkarim BS, Cuartero J, Hanson J, et al. Increased risk of locoregional recurrence for women with T1-2N0 triple-negative breast cancer treated with modified radical mastectomy without adjuvant radiation therapy compared with breast-conserving therapy. J Clin Oncol 2011; 29:2852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/3/41017/abstract/67\">",
"      Wang J, Shi M, Ling R, et al. Adjuvant chemotherapy and radiotherapy in triple-negative breast carcinoma: a prospective randomized controlled multi-center trial. Radiother Oncol 2011; 100:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/3/41017/abstract/68\">",
"      Freedman GM, Fowble BL, Hanlon AL, et al. A close or positive margin after mastectomy is not an indication for chest wall irradiation except in women aged fifty or younger. Int J Radiat Oncol Biol Phys 1998; 41:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/3/41017/abstract/69\">",
"      Truong PT, Olivotto IA, Speers CH, et al. A positive margin is not always an indication for radiotherapy after mastectomy in early breast cancer. Int J Radiat Oncol Biol Phys 2004; 58:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/3/41017/abstract/70\">",
"      McCammon R, Finlayson C, Schwer A, Rabinovitch R. Impact of postmastectomy radiotherapy in T3N0 invasive carcinoma of the breast: a Surveillance, Epidemiology, and End Results database analysis. Cancer 2008; 113:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/3/41017/abstract/71\">",
"      Olson JE, Neuberg D, Pandya KJ, et al. The role of radiotherapy in the management of operable locally advanced breast carcinoma: results of a randomized trial by the Eastern Cooperative Oncology Group. Cancer 1997; 79:1138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/3/41017/abstract/72\">",
"      Kyndi M, S&oslash;rensen FB, Knudsen H, et al. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group. J Clin Oncol 2008; 26:1419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/3/41017/abstract/73\">",
"      Cheng SH, Horng CF, West M, et al. Genomic prediction of locoregional recurrence after mastectomy in breast cancer. J Clin Oncol 2006; 24:4594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/3/41017/abstract/74\">",
"      Metz JM, Schultz DJ, Fox K, et al. Analysis of outcomes for high-risk breast cancer based on interval from surgery to postmastectomy radiation therapy. Cancer J 2000; 6:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/3/41017/abstract/75\">",
"      Recht A, Come SE, Henderson IC, et al. The sequencing of chemotherapy and radiation therapy after conservative surgery for early-stage breast cancer. N Engl J Med 1996; 334:1356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/3/41017/abstract/76\">",
"      Bellon JR, Come SE, Gelman RS, et al. Sequencing of chemotherapy and radiation therapy in early-stage breast cancer: updated results of a prospective randomized trial. J Clin Oncol 2005; 23:1934.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 787 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-60.18.131.125-6AD27EA953-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_3_41017=[""].join("\n");
var outline_f40_3_41017=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RATIONALE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Sites of locoregional recurrence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Risk factors for locoregional recurrence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Axillary nodes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Tumor size",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Extracapsular extension",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Other",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Impact of systemic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Impact of locoregional recurrence on survival",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      POSTMASTECTOMY IRRADIATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Early clinical trials",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Meta-analyses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Modern clinical trials",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Danish trials",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - British Columbia trial",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Limitations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Positive lymph nodes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9984215\">",
"      - Fewer positive nodes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Positive deep margins",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Locally advanced breast cancer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9984477\">",
"      - Guidelines from expert groups",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Timing of treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/787\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/787|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?39/39/40563\" title=\"figure 1\">",
"      Schematic of the breast and regional lymph nodes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/787|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?29/14/29920\" title=\"table 1\">",
"      TNM stage breast cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?4/58/5037\" title=\"table 2\">",
"      Mastectomy chest wall XRT",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/4/37961?source=related_link\">",
"      Adjuvant chemotherapy for hormone receptor-positive or negative, HER2-negative breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/29/39386?source=related_link\">",
"      Breast reconstruction in women with breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/21/34137?source=related_link\">",
"      Cardiotoxicity of radiation therapy for malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/40/34441?source=related_link\">",
"      Epidemiology, risk factors and the clinical approach to ER/PR negative, HER2-negative (Triple-negative) breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/52/42825?source=related_link\">",
"      Management of the regional lymph nodes in breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/46/19177?source=related_link\">",
"      Overview of the treatment of newly diagnosed, non-metastatic breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/7/11385?source=related_link\">",
"      Role of radiation therapy in breast conservation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/46/39657?source=related_link\">",
"      Techniques of breast and chest wall irradiation for early stage breast cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_3_41018="PROMIS domain";
var content_f40_3_41018=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F72832&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F72832&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 780px\">",
"   <div class=\"ttl\">",
"    Patient-Reported Outcomes Measurement Information System (PROMIS) domain framework",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 760px; height: 825px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Subscripts following a + indicate bank variations for specified subgroups.",
"    <br>",
"     A subscript before the bank name indicates the bank was developed in this population only.",
"     <br>",
"      A heavy dark border indicates this instrument is currently available in Assessment Center.",
"      <br>",
"       Global Health includes&nbsp;two calibrated scales and&nbsp;two uncalibrated pool items.",
"       <div class=\"footnotes\">",
"        Ca: cancer; MA: mobility AIDS, HIV.",
"       </div>",
"       <div class=\"reference\">",
"        Reprinted with permission of the PROMIS Health Organization and the PROMIS Cooperative Group. Copyright &copy; 2012.",
"       </div>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_3_41018=[""].join("\n");
var outline_f40_3_41018=null;
var title_f40_3_41019="Epistaxis equipment";
var content_f40_3_41019=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F58901&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F58901&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Epistaxis management equipment list",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Equipment:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gloves, gown, mask, drapes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Emesis basin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tongue depressors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cotton pledgets, cotton swabs, and sterile gauze",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nasal speculum",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bayonet forceps",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Frazier (or comparable) suction catheter",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Syringes (10 and 20 mL)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Angiocatheter (22 gauge)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Isotonic saline; sterile water",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Silver nitrate sticks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Electrical cautery device",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nasal tampons (eg, Merocel&reg;)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nasal balloon catheters (eg, RapidRhino&reg;)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Foley catheter (12 French) and small c-clamp (eg, from nasogastric tube kit)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ribbon gauze",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Medications:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oxymetazoline",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Topical lidocaine (2 percent) or topical cocaine (4 percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Topical antibiotic ointment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Injectable lidocaine (1 or 2 percent) with epinephrine",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_3_41019=[""].join("\n");
var outline_f40_3_41019=null;
var title_f40_3_41020="Pharmacokinetics of quinolones";
var content_f40_3_41020=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F72974&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F72974&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Pharmacokinetics of quinolones",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Quinolone",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose, mg",
"       </td>",
"       <td class=\"subtitle1\">",
"        Cmax, &micro;g/mL",
"       </td>",
"       <td class=\"subtitle1\">",
"        Half-life, hours",
"       </td>",
"       <td class=\"subtitle1\">",
"        Bioavailability, percent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Renal clearance, mL/min",
"       </td>",
"       <td class=\"subtitle1\">",
"        Renal excretion*, percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Norfloxacin",
"       </td>",
"       <td>",
"        400 PO",
"       </td>",
"       <td>",
"        1.5",
"       </td>",
"       <td>",
"        3.3",
"       </td>",
"       <td>",
"        (50)",
"       </td>",
"       <td>",
"        234",
"       </td>",
"       <td>",
"        27",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Ciprofloxacin",
"       </td>",
"       <td>",
"        500 PO",
"       </td>",
"       <td>",
"        2.4",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        70",
"       </td>",
"       <td>",
"        358",
"       </td>",
"       <td>",
"        40",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        400 IV",
"       </td>",
"       <td>",
"        4.6",
"       </td>",
"       <td>",
"        5-6",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        300",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Ofloxacin",
"       </td>",
"       <td>",
"        400 PO",
"       </td>",
"       <td>",
"        4.6",
"       </td>",
"       <td>",
"        4-5",
"       </td>",
"       <td>",
"        &gt;95",
"       </td>",
"       <td>",
"        195",
"       </td>",
"       <td>",
"        73",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        400 IV",
"       </td>",
"       <td>",
"        5.5",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        190",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Levofloxacin",
"       </td>",
"       <td>",
"        500 PO",
"       </td>",
"       <td>",
"        5.7",
"       </td>",
"       <td>",
"        6-8",
"       </td>",
"       <td>",
"        99",
"       </td>",
"       <td>",
"        116",
"       </td>",
"       <td>",
"        77",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        500 IV",
"       </td>",
"       <td>",
"        6.4",
"       </td>",
"       <td>",
"        6-8",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        99",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Moxifloxacin",
"       </td>",
"       <td>",
"        400 PO",
"       </td>",
"       <td>",
"        4.5",
"       </td>",
"       <td>",
"        11-12",
"       </td>",
"       <td>",
"        88",
"       </td>",
"       <td>",
"        43",
"       </td>",
"       <td>",
"        22",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        400 IV",
"       </td>",
"       <td>",
"        4.4",
"       </td>",
"       <td>",
"        8-15",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Gemifloxacin",
"       </td>",
"       <td>",
"        320 PO",
"       </td>",
"       <td>",
"        1.8",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        70",
"       </td>",
"       <td>",
"        150",
"       </td>",
"       <td>",
"        30",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     Cmax: maximum serum concentration; PO: by mouth; IV: intravenous.",
"     <br>",
"      * Cumulative percentage of dose in urine after 24 hours.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_3_41020=[""].join("\n");
var outline_f40_3_41020=null;
var title_f40_3_41021="Carvedilol LVEF dose response";
var content_f40_3_41021=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F57443&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F57443&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 544px\">",
"   <div class=\"ttl\">",
"    Dose-related increase in LVEF with carvedilol in nonischemic cardiomyopathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 524px; height: 295px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Change in left ventricular ejection fraction (LVEF) among patients with dilated cardiomyopathy after the administration of carvedilol. There is a dose-related increase in LVEF in those with nonischemic cardiomyopathy; no such dose-relationship is seen in patients with ischemic cardiomyopathy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Bristow MR, Gilbert EM, Abraham WT, et al. Circulation 1996; 94:2807.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_3_41021=[""].join("\n");
var outline_f40_3_41021=null;
var title_f40_3_41022="Mechanisms of CVT";
var content_f40_3_41022=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F80911&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F80911&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 487px\">",
"   <div class=\"ttl\">",
"    Mechanisms of CVT",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 467px; height: 486px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CSF: cerebrospinal fluid.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_3_41022=[""].join("\n");
var outline_f40_3_41022=null;
var title_f40_3_41023="Calculator: International Prostatism Symptom Score (IPSS)";
var content_f40_3_41023=[" <div id=\"disclaimer\">",
"  The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"  <a href=\"/home/terms-use\" target=\"_blank\">",
"   UpToDate Terms of Use",
"  </a>",
"  &copy;2013 UpToDate, Inc.",
" </div>",
" <div id=\"topicText\">",
"  <div id=\"mc3k\">",
"   <form action=\"\" id=\"IPSS_form\" name=\"IPSS_form\" onreset=\"rrclr();\" onsubmit=\"return false;\">",
"    <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"100%\">",
"     <tr>",
"      <td bgcolor=\"#eeeeee\" width=\"1%\">",
"       <br/>",
"      </td>",
"      <td align=\"left\" bgcolor=\"#eeeeee\">",
"       <span class=\"medCalcFontTitleBox\">",
"        Calculator: International Prostatism Symptom Score (IPSS)",
"       </span>",
"      </td>",
"     </tr>",
"    </table>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <center>",
"     <table cellpadding=\"3\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"      <tr>",
"       <td align=\"left\" colspan=\"3\">",
"        <span class=\"medCalcFontCCTabBold\">",
"         Over the past month, how often have you had a sensation of not emptying your bladder completely after you finished urinating?",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc1\" onclick=\"IPSS_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         Not at all (0 points)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc1\" onclick=\"IPSS_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         Less than 1 time in 5 (1 point)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc1\" onclick=\"IPSS_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         Less than half the time (2 points)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc1\" onclick=\"IPSS_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         About half the time (3 points)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc1\" onclick=\"IPSS_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         More than half the time (4 points)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc1\" onclick=\"IPSS_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         Almost always (5 points)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"3\">",
"        <span class=\"medCalcFontCCTabBold\">",
"         Over the past month, how often have you had to urinate again less than 2 hours after you finished urinating?",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc2\" onclick=\"IPSS_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         Not at all (0 points)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc2\" onclick=\"IPSS_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         Less than 1 time in 5 (1 point)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc2\" onclick=\"IPSS_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         Less than half the time (2 points)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc2\" onclick=\"IPSS_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         About half the time (3 points)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc2\" onclick=\"IPSS_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         More than half the time (4 points)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc2\" onclick=\"IPSS_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         Almost always (5 points)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"3\">",
"        <span class=\"medCalcFontCCTabBold\">",
"         Over the past month, how often have you found you stopped and started again several times when you urinated?",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc3\" onclick=\"IPSS_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         Not at all (0 points)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc3\" onclick=\"IPSS_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         Less than 1 time in 5 (1 point)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc3\" onclick=\"IPSS_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         Less than half the time (2 points)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc3\" onclick=\"IPSS_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         About half the time (3 points)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc3\" onclick=\"IPSS_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         More than half the time (4 points)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc3\" onclick=\"IPSS_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         Almost always (5 points)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"3\">",
"        <span class=\"medCalcFontCCTabBold\">",
"         Over the past month, how often have you found it difficult to postpone urination?",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc4\" onclick=\"IPSS_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         Not at all (0 points)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc4\" onclick=\"IPSS_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         Less than 1 time in 5 (1 point)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc4\" onclick=\"IPSS_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         Less than half the time (2 points)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc4\" onclick=\"IPSS_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         About half the time (3 points)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc4\" onclick=\"IPSS_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         More than half the time (4 points)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc4\" onclick=\"IPSS_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         Almost always (5 points)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"3\">",
"        <span class=\"medCalcFontCCTabBold\">",
"         Over the past month, how often have you had a weak urinary stream?",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc5\" onclick=\"IPSS_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         Not at all (0 points)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc5\" onclick=\"IPSS_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         Less than 1 time in 5 (1 point)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc5\" onclick=\"IPSS_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         Less than half the time (2 points)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc5\" onclick=\"IPSS_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         About half the time (3 points)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc5\" onclick=\"IPSS_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         More than half the time (4 points)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc5\" onclick=\"IPSS_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         Almost always (5 points)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"3\">",
"        <span class=\"medCalcFontCCTabBold\">",
"         Over the past month, how often have you had to push or strain to begin urination?",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc6\" onclick=\"IPSS_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         Not at all (0 points)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc6\" onclick=\"IPSS_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         Less than 1 time in 5 (1 point)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc6\" onclick=\"IPSS_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         Less than half the time (2 points)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc6\" onclick=\"IPSS_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         About half the time (3 points)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc6\" onclick=\"IPSS_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         More than half the time (4 points)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc6\" onclick=\"IPSS_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         Almost always (5 points)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"3\">",
"        <span class=\"medCalcFontCCTabBold\">",
"         Over the past month, how many times did you most typically get up to urinate from the time you went to bed at night until the time you got up in the morning?",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc7\" onclick=\"IPSS_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         None (0 points)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc7\" onclick=\"IPSS_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         1 time (1 point)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc7\" onclick=\"IPSS_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         2 times (2 points)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc7\" onclick=\"IPSS_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         3 times (3 points)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc7\" onclick=\"IPSS_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         4 times (4 points)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc7\" onclick=\"IPSS_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         5 or more times (5 points)",
"        </span>",
"       </td>",
"      </tr>",
"     </table>",
"    </center>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <span class=\"medCalcFontCCTabBold\">",
"     Total Criteria Point Count:",
"    </span>",
"    <input name=\"cctotal\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <center>",
"     <input name=\"reset\" type=\"reset\" value=\"Reset Form\"/>",
"    </center>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"70%\">",
"     <tr>",
"      <td bgcolor=\"#eeeeee\" width=\"1%\">",
"       <br/>",
"      </td>",
"      <td align=\"left\" bgcolor=\"#eeeeee\">",
"       <span class=\"medCalcFontTitleBox\">",
"        IPSS Score",
"       </span>",
"      </td>",
"     </tr>",
"    </table>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <center>",
"     <table border=\"1\" cellpadding=\"4\" cellspacing=\"0\" summary=\"RRTable\">",
"      <tr id=\"rr1_1\">",
"       <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px\">",
"        <span class=\"medCalcFontOneBold\">",
"         0-7 Points:",
"        </span>",
"       </td>",
"       <td align=\"left\" style=\"border-left: 0px;\">",
"        <span class=\"medCalcFontOne\">",
"         Mild symptoms",
"        </span>",
"       </td>",
"      </tr>",
"      <tr id=\"rr1_2\">",
"       <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px\">",
"        <span class=\"medCalcFontOneBold\">",
"         8-19 Points:",
"        </span>",
"       </td>",
"       <td align=\"left\" style=\"border-left: 0px;\">",
"        <span class=\"medCalcFontOne\">",
"         Moderate Symptoms",
"        </span>",
"       </td>",
"      </tr>",
"      <tr id=\"rr1_3\">",
"       <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px\">",
"        <span class=\"medCalcFontOneBold\">",
"         20-35 Points:",
"        </span>",
"       </td>",
"       <td align=\"left\" style=\"border-left: 0px;\">",
"        <span class=\"medCalcFontOne\">",
"         Severe symptoms",
"        </span>",
"       </td>",
"      </tr>",
"     </table>",
"    </center>",
"   </form>",
"   <br/>",
"   &nbsp;",
"   <br/>",
"   <div class=\"references\">",
"    <span class=\"medCalcFontRef\">",
"     <b>",
"      References",
"     </b>",
"    </span>",
"    <ol>",
"     <li>",
"      <span class=\"medCalcFontRef\">",
"       Barry MJ, Fowler FJ Jr, O'Leary MP,et. al. The American Urological Association symptom index for benign prostatic hyperplasia.  The Measurement Committee of the American Urological Association.",
"       <i>",
"        J Urol",
"       </i>",
"       . 1992 Nov;148(5):1549-57.",
"      </span>",
"     </li>",
"    </ol>",
"   </div>",
"   <script language=\"JavaScript1.1\" type=\"text/javascript\">",
"    /* &lt;![CDATA[ */",
"",
";",
"IPSS_fx();",
"/* ]]&gt; */",
"   </script>",
"  </div>",
" </div>",
" <div id=\"topicAgreement\">",
"  Use of UpToDate is subject to the",
"  <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"   Subscription and License Agreement",
"  </a>",
"  .",
" </div>",
" <div id=\"printDisclaimer\">",
"  Information on this page may not appear correctly if printed.",
" </div>",
" <div id=\"disclaimerCalculator\">",
"  <div class=\"medCalcFontTwo\">",
"   <p class=\"header\">",
"    Legal Notices and Disclaimer",
"   </p>",
"   <p>",
"    All information contained in and produced by the MedCalc 3000 system is provided",
"			for educational purposes only. This information should not be used for the diagnosis or treatment",
"			of any health problem or disease.",
"    <b>",
"     THIS INFORMATION IS NOT INTENDED TO REPLACE CLINICAL JUDGMENT OR",
"			GUIDE INDIVIDUAL PATIENT CARE IN ANY MANNER.",
"    </b>",
"    <a class=\"medCalcDisclaimerLink\" href=\"./med-calc-disclaimer\">",
"     Click here for",
"				full notice and disclaimer.",
"    </a>",
"   </p>",
"   <p class=\"copy\">",
"    MedCalc 3000 is Copyright &copy; 1998-2013 Foundation Internet Services",
"   </p>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_3_41023=[" /* <![CDATA[ */",
"",
"var calctxt = '';",
"var xmltxt = '';",
"var htmtxt = '';",
"",
"",
"function IPSS_fx() {",
"with(document.IPSS_form){",
"",
"Score = 0.0;",
"doCalc = true;",
"",
"if (cc1[0].checked){",
"Score = Score + 0;",
"}",
"if (cc1[1].checked){",
"Score = Score + 1;",
"}",
"if (cc1[2].checked){",
"Score = Score + 2;",
"}",
"if (cc1[3].checked){",
"Score = Score + 3;",
"}",
"if (cc1[4].checked){",
"Score = Score + 4;",
"}",
"if (cc1[5].checked){",
"Score = Score + 5;",
"}",
"if (cc2[0].checked){",
"Score = Score + 0;",
"}",
"if (cc2[1].checked){",
"Score = Score + 1;",
"}",
"if (cc2[2].checked){",
"Score = Score + 2;",
"}",
"if (cc2[3].checked){",
"Score = Score + 3;",
"}",
"if (cc2[4].checked){",
"Score = Score + 4;",
"}",
"if (cc2[5].checked){",
"Score = Score + 5;",
"}",
"if (cc3[0].checked){",
"Score = Score + 0;",
"}",
"if (cc3[1].checked){",
"Score = Score + 1;",
"}",
"if (cc3[2].checked){",
"Score = Score + 2;",
"}",
"if (cc3[3].checked){",
"Score = Score + 3;",
"}",
"if (cc3[4].checked){",
"Score = Score + 4;",
"}",
"if (cc3[5].checked){",
"Score = Score + 5;",
"}",
"if (cc4[0].checked){",
"Score = Score + 0;",
"}",
"if (cc4[1].checked){",
"Score = Score + 1;",
"}",
"if (cc4[2].checked){",
"Score = Score + 2;",
"}",
"if (cc4[3].checked){",
"Score = Score + 3;",
"}",
"if (cc4[4].checked){",
"Score = Score + 4;",
"}",
"if (cc4[5].checked){",
"Score = Score + 5;",
"}",
"if (cc5[0].checked){",
"Score = Score + 0;",
"}",
"if (cc5[1].checked){",
"Score = Score + 1;",
"}",
"if (cc5[2].checked){",
"Score = Score + 2;",
"}",
"if (cc5[3].checked){",
"Score = Score + 3;",
"}",
"if (cc5[4].checked){",
"Score = Score + 4;",
"}",
"if (cc5[5].checked){",
"Score = Score + 5;",
"}",
"if (cc6[0].checked){",
"Score = Score + 0;",
"}",
"if (cc6[1].checked){",
"Score = Score + 1;",
"}",
"if (cc6[2].checked){",
"Score = Score + 2;",
"}",
"if (cc6[3].checked){",
"Score = Score + 3;",
"}",
"if (cc6[4].checked){",
"Score = Score + 4;",
"}",
"if (cc6[5].checked){",
"Score = Score + 5;",
"}",
"if (cc7[0].checked){",
"Score = Score + 0;",
"}",
"if (cc7[1].checked){",
"Score = Score + 1;",
"}",
"if (cc7[2].checked){",
"Score = Score + 2;",
"}",
"if (cc7[3].checked){",
"Score = Score + 3;",
"}",
"if (cc7[4].checked){",
"Score = Score + 4;",
"}",
"if (cc7[5].checked){",
"Score = Score + 5;",
"}",
"cctotal.value = Score;",
"",
"if (doCalc){",
"",
"rrclr();",
"if ((Score >= 0) && (Score <= 7)){ document.getElementById('rr1_1').bgColor = \"#cccccc\";",
"}",
"if ((Score >= 8) && (Score <= 19)){ document.getElementById('rr1_2').bgColor = \"#cccccc\";",
"}",
"if ((Score >= 20) && (Score <= 35)){ document.getElementById('rr1_3').bgColor = \"#cccccc\";",
"}",
"",
"",
"",
"}",
"}",
"}",
"",
"",
"",
"",
"function rrclr(){",
"document.getElementById('rr1_1').bgColor = \"\";",
"document.getElementById('rr1_2').bgColor = \"\";",
"document.getElementById('rr1_3').bgColor = \"\";",
"}",
"",
"",
"/* ]]> */"].join("\n");
var outline_f40_3_41023=null;
